

Longitudinal studies of cognition and functional outcomes for MATRICS

Schizophrenia Research

72, 41-51

DOI: [10.1016/j.schres.2004.09.009](https://doi.org/10.1016/j.schres.2004.09.009)

Citation Report

#	ARTICLE	IF	CITATIONS
1	NIMH-MATRICES survey on assessment of neurocognition in schizophrenia. Schizophrenia Research, 2004, 72, 11-19.	1.1	106
2	The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophrenia Research, 2004, 72, 1-3.	1.1	242
3	Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. Journal of the International Neuropsychological Society, 2005, 11, 727-36.	1.2	113
4	Stimulating development of new drugs to improve cognition in schizophrenia. Current Psychosis & Therapeutics Reports, 2005, 3, 68-73.	0.1	1
5	Comparative behavioral changes in postpubertal rats after neonatal excitotoxic lesions of the ventral hippocampus and the prefrontal cortex. Synapse, 2005, 56, 147-153.	0.6	40
6	Measuring Changes in Functional Status Among Patients With Schizophrenia: The Link With Cognitive Impairment. Schizophrenia Bulletin, 2005, 32, 666-678.	2.3	74
7	Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia. Schizophrenia Bulletin, 2005, 31, 830-853.	2.3	105
8	Cognitive Rehabilitation for Schizophrenia and the Putative Role of Motivation and Expectancies. Schizophrenia Bulletin, 2005, 32, 474-485.	2.3	162
9	A Collaborative Approach to Targeted Treatment Development for Schizophrenia: A Qualitative Evaluation of the NIMH-MATRICES Project. Schizophrenia Bulletin, 2005, 31, 954-961.	2.3	19
10	The course of cognitive functioning in first episode psychosis: Changes over time and impact on outcome. Schizophrenia Research, 2005, 78, 35-43.	1.1	138
11	Functional brain imaging of symptoms and cognition in schizophrenia. Progress in Brain Research, 2005, 150, 299-604.	0.9	36
12	Recent Advances in Social Skills Training for Schizophrenia. Schizophrenia Bulletin, 2006, 32, S12-S23.	2.3	259
13	Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence. Journal of Dual Diagnosis, 2006, 2, 53-69.	0.7	5
14	Treatment-Refractory Schizophrenia in Children and Adolescents: An Update on Clozapine and Other Pharmacologic Interventions. Child and Adolescent Psychiatric Clinics of North America, 2006, 15, 135-159.	1.0	20
15	Real-World Cognitive--and Metacognitive--Dysfunction in Schizophrenia: A New Approach for Measuring (and Remediating) More "Right Stuff". Schizophrenia Bulletin, 2006, 32, 310-326.	2.3	267
16	Associating functional recovery with neurocognitive profiles identified using partially ordered classification models. Schizophrenia Research, 2006, 85, 40-48.	1.1	18
17	Deficits in memory strategy use are related to verbal memory impairments in adolescents with schizophrenia-spectrum disorders. Schizophrenia Research, 2006, 85, 201-212.	1.1	39
18	Neurocognition and suicidal behaviour in an Irish population with major psychotic disorders. Schizophrenia Research, 2006, 85, 196-200.	1.1	69

#	ARTICLE	IF	CITATIONS
21	Translating basic attentional paradigms to schizophrenia research: Reconsidering the nature of the deficits. <i>Development and Psychopathology</i> , 2006, 18, 831-51.	1.4	27
22	Social outcomes in schizophrenia: from description to action. <i>Current Opinion in Psychiatry</i> , 2006, 19, 140-144.	3.1	14
23	Reliability and validity of communication skills questionnaire (CSQ). <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 211-218.	1.0	25
24	The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. <i>Psychopharmacology</i> , 2006, 187, 312-320.	1.5	117
25	The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. <i>Psychopharmacology</i> , 2006, 187, 356-363.	1.5	55
26	The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps?. <i>Neurotoxicity Research</i> , 2006, 10, 211-220.	1.3	144
28	An "Errorful" Learning Deficit in Schizophrenia?. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006, 28, 101-110.	0.8	29
29	Social Perception as a Mediator of the Influence of Early Visual Processing on Functional Status in Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 448-454.	4.0	296
30	Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning. <i>American Journal of Psychiatry</i> , 2006, 163, 1918-1925.	4.0	105
31	Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms. <i>American Journal of Psychiatry</i> , 2006, 163, 418-425.	4.0	660
32	The Role of Neurocognition and Social Context in Predicting Community Functioning Among Formerly Homeless Seriously Mentally Ill Persons. <i>Schizophrenia Bulletin</i> , 2006, 33, 1388-1396.	2.3	27
33	Closing the Gap Between Cognitive Performance and Real-World Functional Outcome in Schizophrenia: The Importance of Metacognition. <i>Current Psychiatry Reviews</i> , 2006, 2, 189-198.	0.9	8
34	Integrated Psychological Therapy (IPT) for Schizophrenia: Is It Effective?. <i>Schizophrenia Bulletin</i> , 2006, 32, S81-S93.	2.3	212
35	Cognitive Predictors of Social Functioning Improvements Following Cognitive Remediation for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2006, 32, S123-S131.	2.3	68
36	Psychomotor Slowing in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 33, 1038-1053.	2.3	204
37	The Stability of Inhibitory and Working Memory Deficits in Children and Adolescents Who are Children of Parents With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 47-51.	2.3	16
38	Cognitive Neuroscience-Based Approaches to Measuring and Improving Treatment Effects on Cognition in Schizophrenia: The CNTRICS Initiative. <i>Schizophrenia Bulletin</i> , 2007, 33, 1131-1137.	2.3	256
39	The quest for developing new treatments from imaging techniques: promises, problems and future potential. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 1029-1033.	2.5	3

#	ARTICLE	IF	CITATIONS
41	Preliminary Findings for Two New Measures of Social and Role Functioning in the Prodromal Phase of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 33, 688-702.	2.3	484
42	Cognition in Young Schizophrenia Outpatients: Comparison of First-Episode With Multipisode Patients. <i>Schizophrenia Bulletin</i> , 2007, 34, 544-554.	2.3	48
43	Cognitive Improvement in Response to Antipsychotic Drugs. <i>Archives of General Psychiatry</i> , 2007, 64, 631.	13.8	39
44	The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 173-186.	0.0	3
45	How Neurocognition and Social Cognition Influence Functional Change During Community-Based Psychosocial Rehabilitation for Individuals with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 33, 1247-1256.	2.3	155
46	Cognition as an outcome measure in schizophrenia. <i>British Journal of Psychiatry</i> , 2007, 191, s46-s51.	1.7	72
47	Add-on Therapy With Acetylcholinesterase Inhibitors for Memory Dysfunction in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2007, 30, 218-229.	0.2	32
48	The impact of monetary reward on memory in schizophrenia spectrum disorder.. <i>Neuropsychology</i> , 2007, 21, 631-645.	1.0	10
49	Criterion B (social dysfunction) in persons with schizophrenia: the puzzle. <i>Current Opinion in Psychiatry</i> , 2007, 20, 582-587.	3.1	14
50	Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2007, 30, 169-182.	0.2	17
51	The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). <i>Psychiatry Research</i> , 2007, 151, 55-66.	1.7	49
52	Visual-spatial learning and memory in schizotypal personality disorder: Continued evidence for the importance of working memory in the schizophrenia spectrum. <i>Archives of Clinical Neuropsychology</i> , 2007, 22, 109-116.	0.3	26
53	Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. <i>European Neuropsychopharmacology</i> , 2007, 17, 725-734.	0.3	13
54	Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. <i>European Psychiatry</i> , 2007, 22, 104-115.	0.1	139
55	P.3.c.037 Neuropsychological performance and cognitive disability in schizophrenia outpatients. <i>European Neuropsychopharmacology</i> , 2007, 17, S445-S446.	0.3	0
56	P.3.c.038 Effects of high doses of amisulpride in psychotic patients not responding to conventional antipsychotics. <i>European Neuropsychopharmacology</i> , 2007, 17, S446-S447.	0.3	0
57	Functional Genomics and Schizophrenia: Endophenotypes and Mutant Models. <i>Psychiatric Clinics of North America</i> , 2007, 30, 365-399.	0.7	40
58	Social/Communication Skills, Cognition, and Vocational Functioning in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 33, 1213-1220.	2.3	114

#	ARTICLE	IF	CITATIONS
59	Methods for treating cognitive deficits in schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 281-287.	1.4	10
60	Using Event Related Potentials to Explore Stages of Facial Affect Recognition Deficits in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 679-687.	2.3	83
61	Stimulating the Development of Drug Treatments to Improve Cognition in Schizophrenia. <i>Annual Review of Clinical Psychology</i> , 2007, 3, 159-180.	6.3	75
62	Neurocognitive Deficits in Adolescents With Schizophrenia: Longitudinal Stability and Predictive Utility for Short-Term Functional Outcome. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 867-878.	0.3	85
63	Deficits in cue detection and intention retrieval underlie prospective memory impairment in schizophrenia. <i>Schizophrenia Research</i> , 2007, 90, 344-350.	1.1	64
64	Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: An exploratory randomized controlled trial. <i>Schizophrenia Research</i> , 2007, 94, 221-230.	1.1	179
65	Social cognitive impairments in first episode psychosis. <i>Schizophrenia Research</i> , 2007, 95, 124-133.	1.1	111
66	Duration of untreated psychosis and neuropsychological function in first episode psychosis. <i>Schizophrenia Research</i> , 2007, 95, 103-110.	1.1	58
67	Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives. <i>Schizophrenia Research</i> , 2007, 97, 35-42.	1.1	28
68	Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine. <i>Schizophrenia Research</i> , 2007, 96, 146-155.	1.1	40
69	Cognitive alterations in groups at risk for psychosis: neutral markers of genetic risk or indicators of social disability?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 253-262.	2.2	15
70	The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 119-124.	2.2	46
71	Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. <i>Biochemical Pharmacology</i> , 2007, 73, 1123-1134.	2.0	74
72	Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. <i>Psychopharmacology</i> , 2007, 193, 521-537.	1.5	104
73	Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 258, 48-58.	1.8	45
74	Developing translational animal models for symptoms of schizophrenia or bipolar mania. <i>Neurotoxicity Research</i> , 2008, 14, 71-78.	1.3	81
75	Is processing speed predictive of functional outcome in psychosis?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 437-444.	1.6	6
76	Neurocognitive endophenotypes for bipolar disorder. <i>Bipolar Disorders</i> , 2008, 10, 387-399.	1.1	67

#	ARTICLE	IF	CITATIONS
77	Can learning potential in schizophrenia be assessed with the standard CVLT? An exploratory study. <i>Scandinavian Journal of Psychology</i> , 2008, 49, 179-186.	0.8	17
78	Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. <i>Journal of Affective Disorders</i> , 2008, 109, 286-299.	2.0	256
79	Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 89, 352-359.	1.3	22
80	Muscarinic acetylcholine receptors as CNS drug targets. , 2008, 117, 232-243.		369
81	Social and cognitive functioning in psychosis. <i>Schizophrenia Research</i> , 2008, 99, 176-181.	1.1	92
82	Clinical global impression of cognition in schizophrenia (CGI-CogS): Reliability and validity of a co-primary measure of cognition. <i>Schizophrenia Research</i> , 2008, 106, 59-69.	1.1	75
83	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 139-148.	1.1	78
84	General and social cognition in first episode schizophrenia: Identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. <i>Schizophrenia Research</i> , 2008, 99, 182-191.	1.1	92
85	Reduced frontopolar activation during verbal fluency task in schizophrenia: A multi-channel near-infrared spectroscopy study. <i>Schizophrenia Research</i> , 2008, 99, 250-262.	1.1	259
86	Neuropsychological substrates and everyday functioning implications of prospective memory impairment in schizophrenia. <i>Schizophrenia Research</i> , 2008, 106, 42-49.	1.1	72
87	Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: Testing mediator and moderator effects. <i>Schizophrenia Research</i> , 2008, 105, 95-104.	1.1	185
88	Cognitive Neuroscience and Schizophrenia: Translational Research in Need of a Translator. <i>Biological Psychiatry</i> , 2008, 64, 2-3.	0.7	21
89	The Dual-State Theory of Prefrontal Cortex Dopamine Function with Relevance to Catechol-O-Methyltransferase Genotypes and Schizophrenia. <i>Biological Psychiatry</i> , 2008, 64, 739-749.	0.7	470
90	A large-scale cross-sectional and longitudinal study into the ecological validity of neuropsychological test measures in neurologically intact people. <i>Archives of Clinical Neuropsychology</i> , 2008, 23, 787-800.	0.3	63
91	P3 and delta band responses in visual oddball paradigm in schizophrenia. <i>Neuroscience Letters</i> , 2008, 440, 304-308.	1.0	89
92	Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: A naturalistic 6-month follow-up study. <i>Archives of Clinical Neuropsychology</i> , 2008, 23, 271-282.	0.3	14
93	The selective $\alpha 7$ nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: Differential effects in the juvenile and adult rat. <i>Neuroscience</i> , 2008, 154, 741-753.	1.1	24
94	Essential polyunsaturated fatty acids and social cognition in schizophrenia. <i>Psychiatry Research</i> , 2008, 157, 87-93.	1.7	37

#	ARTICLE	IF	CITATIONS
95	Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia. <i>Psychiatry Research</i> , 2008, 158, 11-17.	1.7	35
96	Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication. <i>Psychiatry Research</i> , 2008, 160, 316-326.	1.7	34
97	Predictors of outcome three years after diagnosis of first episode psychosis. <i>Psychiatry Research</i> , 2008, 161, 11-18.	1.7	17
98	Cognitive functioning related to quality of life in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 280-287.	2.5	53
100	Symptoms versus neurocognition as predictors of change in life skills in schizophrenia after outpatient rehabilitation. <i>Schizophrenia Research</i> , 2008, 102, 303-311.	1.1	84
101	Social Cognition Training for Individuals with Schizophrenia: Emerging Evidence. <i>American Journal of Psychiatric Rehabilitation</i> , 2008, 11, 205-252.	0.7	95
102	Transient and selective overexpression of D ₂ receptors in the striatum causes persistent deficits in conditional associative learning. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16027-16032.	3.3	63
103	Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Neuropsychopharmacology</i> , 2008, 33, 1217-1228.	2.8	135
104	The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. <i>Neuropsychopharmacology</i> , 2008, 33, 2061-2079.	2.8	183
105	The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. <i>American Journal of Psychiatry</i> , 2008, 165, 203-213.	4.0	1,863
107	Neurobiology of the early course of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1093-1100.	1.4	14
108	Pretreatment predictors of cognitive deficits in early psychosis. <i>Psychological Medicine</i> , 2008, 38, 737-746.	2.7	24
109	Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 479-488.	1.2	97
110	Intrinsic motivation in schizophrenia: Relationships to cognitive function, depression, anxiety, and personality.. <i>Journal of Abnormal Psychology</i> , 2008, 117, 776-787.	2.0	97
111	Cognitive, clinical, and functional characteristics of verbally superior schizophrenia patients.. <i>Neuropsychology</i> , 2008, 22, 321-328.	1.0	34
112	A Longitudinal Study of Learning Potential and Rehabilitation Outcome in Schizophrenia. <i>Psychiatric Services</i> , 2008, 59, 248-255.	1.1	41
113	An Exploratory Analysis of Neurocognition in Methamphetamine-induced Psychotic Disorder and Paranoid Schizophrenia. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 98-103.	0.5	37
114	Complete and incomplete recovery from first-episode psychosis. , 0, , 201-222.		3

#	ARTICLE	IF	CITATIONS
115	Premorbid cognitive deficits in young relatives of schizophrenia patients. <i>Frontiers in Human Neuroscience</i> , 2009, 3, 62.	1.0	63
116	Using the Wisconsin Card Sorting Test to assess learning potential in normal IQ schizophrenia: Does it have potential?. <i>Nordic Journal of Psychiatry</i> , 2009, 63, 405-411.	0.7	4
117	Role of the cholinergic system in the pathology and treatment of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 73-86.	1.4	35
118	Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 574-590.	1.3	261
119	Age at onset and cognition in schizophrenia: meta-analysis. <i>British Journal of Psychiatry</i> , 2009, 195, 286-293.	1.7	307
120	Muscarinic Receptors in Psychiatric Disorders – Can We Mimic ’Health’?. <i>NeuroSignals</i> , 2009, 17, 298-310.	0.5	23
121	Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 17957-17962.	3.3	191
122	Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem. <i>Schizophrenia Bulletin</i> , 2009, 35, 403-414.	2.3	121
123	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. <i>PLoS Genetics</i> , 2009, 5, e1000373.	1.5	383
124	Social Disinterest Attitudes and Group Cognitive-Behavioral Social Skills Training for Functional Disability in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 874-883.	2.3	60
125	Errorless Learning for Training Individuals With Schizophrenia at a Community Mental Health Setting Providing Work Experience. <i>Schizophrenia Bulletin</i> , 2009, 35, 807-815.	2.3	31
126	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2009, 31, 848-859.	0.8	156
127	Implementation Practice and Implementation Research. <i>Research on Social Work Practice</i> , 2009, 19, 592-601.	1.1	23
128	Neurocognitive change, functional change and service intensity during community-based psychosocial rehabilitation for schizophrenia. <i>Psychological Medicine</i> , 2009, 39, 1637.	2.7	39
129	Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 248-257.	1.3	26
130	Subchronic MK-801 behavioural deficits in rats: Partial reversal by the novel nitrate GT 1061. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 91, 495-502.	1.3	24
131	Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2009, 173, 88-93.	0.9	27
132	Clozapine attenuates disruptions in response inhibition and task efficiency induced by repeated phencyclidine administration in the intracranial self-stimulation procedure. <i>European Journal of Pharmacology</i> , 2009, 602, 78-84.	1.7	19

#	ARTICLE	IF	CITATIONS
133	Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality. <i>Human Psychopharmacology</i> , 2009, 24, 619-627.	0.7	20
134	Neuropsychological performance is related to current social and occupational functioning in veterans with posttraumatic stress disorder. <i>Depression and Anxiety</i> , 2009, 26, 7-15.	2.0	69
135	Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 483-489.	1.8	37
136	Cognitive Remediation in Schizophrenia. <i>Neuropsychology Review</i> , 2009, 19, 353-364.	2.5	265
137	Neuropsychological abnormalities in schizophrenia and major mood disorders: Similarities and differences. <i>Current Psychiatry Reports</i> , 2009, 11, 313-319.	2.1	80
138	The effects of psychotomimetic and putative cognitive-enhancing drugs on the performance of a n-back working memory task in rats. <i>Psychopharmacology</i> , 2009, 202, 67-78.	1.5	18
139	The role of cannabis in cognitive functioning of patients with schizophrenia. <i>Psychopharmacology</i> , 2009, 205, 45-52.	1.5	87
140	Age-dependent discrepancies between computerized and paper cognitive testing in patients with schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 73-77.	1.6	2
141	The Self-Assessment Scale of Cognitive Complaints in Schizophrenia: A validation study in Tunisian population. <i>BMC Psychiatry</i> , 2009, 9, 66.	1.1	15
142	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. <i>European Journal of Human Genetics</i> , 2009, 17, 946-957.	1.4	89
143	Schizophrenia: genetics, prevention and rehabilitation. <i>Acta Neuropsychiatrica</i> , 2009, 21, 109-120.	1.0	9
144	A multi-site Canadian perspective: examining the functional outcome from first-episode psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2009, 120, 138-146.	2.2	56
145	Factors associated with functional psychosocial status in first-episode psychosis. <i>Microbial Biotechnology</i> , 2009, 3, 35-43.	0.9	5
146	What We Know: Findings That Every Theory of Schizophrenia Should Explain. <i>Schizophrenia Bulletin</i> , 2009, 35, 493-508.	2.3	117
147	The Effects of Cognitive Rehabilitation on Social Knowledge in Patients with Schizophrenia. <i>Applied Neuropsychology</i> , 2009, 16, 158-164.	1.5	13
148	Affect recognition as an independent social function determinant in schizophrenia. <i>Comprehensive Psychiatry</i> , 2009, 50, 443-452.	1.5	43
149	The needs of older adults with schizophrenia Implications for psychological interventions. <i>Clinical Psychology Review</i> , 2009, 29, 68-76.	6.0	27
150	Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. <i>Neuropharmacology</i> , 2009, 56, 788-797.	2.0	52

#	ARTICLE	IF	CITATIONS
151	Î±7 Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. <i>Neuropharmacology</i> , 2009, 56, 1001-1009.	2.0	73
152	Social problem-solving in high-functioning schizophrenia: Specific deficits in sending skills. <i>Psychiatry Research</i> , 2009, 165, 215-223.	1.7	12
153	Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 373-379.	2.5	35
154	Bridging the gap between schizophrenia and psychotic mood disorders: Relating neurocognitive deficits to psychopathology. <i>Schizophrenia Research</i> , 2009, 107, 69-75.	1.1	56
155	Social cognitive skills training in schizophrenia: An initial efficacy study of stabilized outpatients. <i>Schizophrenia Research</i> , 2009, 107, 47-54.	1.1	206
156	A comparison of remediation techniques on the Wisconsin Card Sorting Test in schizophrenia. <i>Schizophrenia Research</i> , 2009, 107, 76-82.	1.1	22
157	Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function. <i>Schizophrenia Research</i> , 2009, 107, 275-285.	1.1	40
158	Predictors of change in life skills in schizophrenia after cognitive remediation. <i>Schizophrenia Research</i> , 2009, 107, 267-274.	1.1	88
159	Psychopathology and cognition in divergent functional outcomes in schizophrenia. <i>Schizophrenia Research</i> , 2009, 109, 46-51.	1.1	19
160	Pathways to functional outcomes in schizophrenia: The role of premorbid functioning, negative symptoms and intelligence. <i>Schizophrenia Research</i> , 2009, 110, 40-46.	1.1	42
161	Elementary neurocognitive function, facial affect recognition and social-skills in schizophrenia. <i>Schizophrenia Research</i> , 2009, 110, 173-179.	1.1	64
162	Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. <i>Schizophrenia Research</i> , 2009, 112, 181-186.	1.1	36
163	Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2009, 113, 189-199.	1.1	462
164	Progressive gray matter changes in first episode schizophrenia: A 4-year longitudinal magnetic resonance study using VBM. <i>Schizophrenia Research</i> , 2009, 114, 136-143.	1.1	94
165	Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. <i>Schizophrenia Research</i> , 2009, 115, 104-114.	1.1	102
166	Lurasidone: a new drug in development for schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1715-1726.	1.9	115
167	A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. <i>Human Molecular Genetics</i> , 2009, 18, 4650-4661.	1.4	131
168	Psychosocial Treatments to Promote Functional Recovery in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 347-361.	2.3	223

#	ARTICLE	IF	CITATIONS
169	Attention Shaping: a Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 222-232.	2.3	79
170	A Systematic Review of Cognitive Deficits in Homeless Adults: Implications for Service Delivery. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 123-133.	0.9	61
171	Improving health, well-being and cognition in schizophrenia: making the case for physical activity. <i>Journal of Public Mental Health</i> , 2010, 9, 32-35.	0.8	1
172	IQ Subtypes in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 580-585.	0.5	31
173	Phencyclidine withdrawal disrupts episodic-like memory in rats: reversal by donepezil but not clozapine. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1011-1020.	1.0	15
174	Habituation in prepulse inhibition is affected by a polymorphism on the NMDA receptor 2B subunit gene (GRIN2B). <i>Psychiatric Genetics</i> , 2010, 20, 191-198.	0.6	17
175	Distinct Contribution of Working Memory and Social Comprehension Failures in Neuropsychological Impairment in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 206-212.	0.5	10
176	A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 138-149.	1.1	345
177	Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms. <i>Focus (American Psychiatric Publishing)</i> , 2010, 8, 638-646.	0.4	6
178	Are working memory deficits in bipolar disorder markers for psychosis?. <i>Neuropsychology</i> , 2010, 24, 244-254.	1.0	29
182	Somatosensory System Deficits in Schizophrenia Revealed by MEG during a Median-Nerve Oddball Task. <i>Brain Topography</i> , 2010, 23, 82-104.	0.8	51
183	Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. <i>Journal of Psychiatric Research</i> , 2010, 44, 294-301.	1.5	92
184	Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats. <i>European Journal of Pharmacology</i> , 2010, 639, 67-80.	1.7	31
185	Assessing cognitive function in clinical trials of schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 1161-1177.	2.9	152
186	The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. <i>BMC Psychiatry</i> , 2010, 10, 47.	1.1	13
187	A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. <i>Annals of General Psychiatry</i> , 2010, 9, 27.	1.2	75
188	Research Review: Cholinergic mechanisms, early brain development, and risk for schizophrenia. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 535-549.	3.1	50
189	Goal Representations and Motivational Drive in Schizophrenia: The Role of Prefrontal-Striatal Interactions. <i>Schizophrenia Bulletin</i> , 2010, 36, 919-934.	2.3	415

#	ARTICLE	IF	CITATIONS
190	Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis. Schizophrenia Bulletin, 2010, 36, 43-47.	2.3	38
191	Sustained Attention and Planning Deficits but Intact Attentional Set-Shifting in Neuroleptic-Na ⁺ -ve First-Episode Schizophrenia Patients. Neuropsychobiology, 2010, 61, 79-86.	0.9	31
192	A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 419-427.	2.3	73
193	Cognitive Performance and Functional Competence as Predictors of Community Independence in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 381-387.	2.3	43
194	Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia. Psychological Medicine, 2010, 40, 935-944.	2.7	60
195	Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. Journal of Psychopharmacology, 2010, 24, 407-419.	2.0	27
196	The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Expert Opinion on Investigational Drugs, 2010, 19, 1217-1233.	1.9	32
197	Declarative and nondeclarative memory in schizophrenia: What is impaired? What is spared?. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 1017-1027.	0.8	22
198	The Relevance of Neurocognition and Social Cognition for Outcome and Recovery in Schizophrenia. Key Issues in Mental Health, 2010, , 23-36.	0.6	9
199	The Prospective Relationships Among Intrinsic Motivation, Neurocognition, and Psychosocial Functioning in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 935-948.	2.3	107
200	Neurocognitive Decline in Early-Onset Schizophrenia Compared With ADHD and Normal Controls: Evidence From a 13-Year Follow-up Study. Schizophrenia Bulletin, 2010, 36, 557-565.	2.3	61
201	Assessing Function and Functional Outcome in Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 3-21.	0.8	39
202	Definition and Measurement of Neurocognition and Social Cognition. Key Issues in Mental Health, 2010, , 1-22.	0.6	8
203	Cognitive Improvement by Activation of $\alpha 7$ Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology. Current Pharmaceutical Design, 2010, 16, 323-343.	0.9	182
204	Social Functioning Among Older Community-Dwelling Patients With Schizophrenia: A Review. American Journal of Geriatric Psychiatry, 2010, 18, 862-878.	0.6	43
205	Psychosocial function in schizophrenia and bipolar disorder: Relationship to neurocognition and clinical symptoms. Journal of the International Neuropsychological Society, 2010, 16, 771-783.	1.2	60
206	Mismatch Negativity, Social Cognition, and Functioning in Schizophrenia Patients. Biological Psychiatry, 2010, 67, 940-947.	0.7	160
207	Disruption of Performance in the Five-Choice Serial Reaction Time Task Induced By Administration of N-Methyl-D-Aspartate Receptor Antagonists: Relevance to Cognitive Dysfunction in Schizophrenia. Biological Psychiatry, 2010, 68, 5-16.	0.7	113

#	ARTICLE	IF	CITATIONS
208	Elementary neurocognitive function, learning potential and everyday life skills in schizophrenia: What is their relationship?. Schizophrenia Research, 2010, 116, 280-288.	1.1	28
209	Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia. Schizophrenia Research, 2010, 122, 156-163.	1.1	36
210	An investigation of 3 neurocognitive subtypes in schizophrenia. Schizophrenia Research, 2010, 121, 32-38.	1.1	24
211	The ecological validity of everyday cognition in hospitalized patients with serious mental illness. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 299-308.	0.8	11
212	Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia. Psychiatry Research, 2010, 177, 41-45.	1.7	66
213	Neuroprotective Effects of Cognitive Enhancement Therapy Against Gray Matter Loss in Early Schizophrenia. Archives of General Psychiatry, 2010, 67, 674.	13.8	306
214	Effects on cognitive functioning after olanzapineâ€“ziprasidone crossover in recent-onset schizophrenia. European Neuropsychopharmacology, 2010, 20, 907-912.	0.3	9
215	Neuropsychology of Treatment-Resistant Schizophrenia. Advances in Biological Psychiatry, 2010, , 33-51.	0.2	3
216	Neuroplasticity-Based Cognitive Training in Schizophrenia: An Interim Report on the Effects 6 Months Later. Schizophrenia Bulletin, 2010, 36, 869-879.	2.3	211
217	Adaptive Competence Impairment and Cognitive Deficits in Acutely Ill Schizophrenia Patients Residing in Nursing Homes. American Journal of Geriatric Psychiatry, 2011, 19, 752-756.	0.6	12
218	The portuguese version of the personal and social performance scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients. European Psychiatry, 2011, 26, 1442-1442.	0.1	0
219	A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. Biological Psychiatry, 2011, 69, 442-449.	0.7	155
220	Sex differences in neuropsychological performance and social functioning in schizophrenia and bipolar disorder.. Neuropsychology, 2011, 25, 499-510.	1.0	86
221	General functioning predicts reward and punishment learning in schizophrenia. Schizophrenia Research, 2011, 127, 131-136.	1.1	42
222	Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophrenia Research, 2011, 126, 257-264.	1.1	162
223	Executive functioning correctly classified diagnoses in patients with first-episode psychosis: Evidence from a 2-year longitudinal study. Schizophrenia Research, 2011, 126, 77-80.	1.1	20
224	Cognition at illness onset as a predictor of later functional outcome in early psychosis: Systematic review and methodological critique. Schizophrenia Research, 2011, 125, 221-235.	1.1	159
225	Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: What is their relationship?. Schizophrenia Research, 2011, 127, 157-162.	1.1	76

#	ARTICLE	IF	CITATIONS
226	A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophrenia. <i>Schizophrenia Research</i> , 2011, 130, 123-129.	1.1	79
227	Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis. <i>Schizophrenia Research</i> , 2011, 130, 164-169.	1.1	37
228	Acute psychopathology as a predictor of global functioning in patients with ICD-10 non-affective psychosis: A prospective study in 11 European countries. <i>Schizophrenia Research</i> , 2011, 131, 105-111.	1.1	15
229	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: A comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). <i>Schizophrenia Research</i> , 2011, 130, 137-142.	1.1	44
230	Neurocognitive predictors of functional outcome two to 13years after identification as ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2011, 132, 1-7.	1.1	182
231	Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits. <i>Schizophrenia Research</i> , 2011, 132, 24-27.	1.1	128
232	Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: A prospective study in a real-world setting. <i>Schizophrenia Research</i> , 2011, 133, 223-231.	1.1	57
233	ZNF804A risk allele is associated with relatively intact gray matter volume in patients with schizophrenia. <i>NeuroImage</i> , 2011, 54, 2132-2137.	2.1	78
234	Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): A study protocol for a centrally randomised, observer-blinded multi-centre clinical trial. <i>Trials</i> , 2011, 12, 35.	0.7	20
235	Impact des déficits cognitifs dans les activités de la vie quotidienne des personnes souffrant de schizophrénie. <i>Annales Medico-Psychologiques</i> , 2011, 169, 171-174.	0.2	9
236	Neurocognitive functioning and suicidality in schizophrenia spectrum disorders. <i>Comprehensive Psychiatry</i> , 2011, 52, 156-163.	1.5	49
237	Neuropsychologic profile of college students with schizotypal traits. <i>Comprehensive Psychiatry</i> , 2011, 52, 511-516.	1.5	26
238	Neurocognition as a predictor of response to evidence-based psychosocial interventions in schizophrenia: What is the state of the evidence?. <i>Clinical Psychology Review</i> , 2011, 31, 663-672.	6.0	77
239	Further evidence for the efficacy of a metacognitive group training in schizophrenia. <i>Behaviour Research and Therapy</i> , 2011, 49, 151-157.	1.6	151
240	The developmental course of executive functioning in schizophrenia. <i>International Journal of Developmental Neuroscience</i> , 2011, 29, 237-243.	0.7	46
241	Receptor screening technologies in the evaluation of Amazonian ethnomedicines with potential applications to cognitive deficits. <i>Journal of Ethnopharmacology</i> , 2011, 134, 475-492.	2.0	11
242	Real world functioning in schizophrenia patients and healthy adults: Assessing validity of the Multidimensional Scale of Independent Functioning. <i>Psychiatry Research</i> , 2011, 186, 123-127.	1.7	8
243	Neurocognition and recovery in first episode psychosis. <i>Psychiatry Research</i> , 2011, 188, 1-6.	1.7	40

#	ARTICLE	IF	CITATIONS
244	The association between verbal memory, processing speed, negative symptoms and functional capacity in schizophrenia. <i>Psychiatry Research</i> , 2011, 187, 329-334.	1.7	20
245	Neurocognition and occupational functioning in patients with first-episode psychosis: A 2-year follow-up study. <i>Psychiatry Research</i> , 2011, 188, 334-342.	1.7	41
247	Psychopathologic, neuropsychological and functional outcome measures during cognitive rehabilitation in schizophrenia: A prospective controlled study in a real-world setting. <i>European Psychiatry</i> , 2011, 26, 276-283.	0.1	24
248	Cognition dopamine and bioactive lipids in schizophrenia. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 298-330.	0.8	46
249	Criterion and Construct Validity of the CogState Schizophrenia Battery in Japanese Patients with Schizophrenia. <i>PLoS ONE</i> , 2011, 6, e20469.	1.1	34
250	Intrinsic Motivation as a Predictor of Work Outcome After Vocational Rehabilitation in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 672-677.	0.5	60
251	Housing Status as an Independent Predictor of Functional Capacity in Patients With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 854-860.	0.5	25
252	Cognitive and Clinical Factors Are Associated With Service Engagement in Early-Phase Schizophrenia Spectrum Disorders. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 176-182.	0.5	32
253	A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 221-225.	0.7	35
254	Cognition and Global Assessment of Functioning in Male and Female Outpatients With Schizophrenia Spectrum Disorders. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 445-448.	0.5	23
255	Effects of Acamprosate on Cognition in a Treatment Study of Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 499-505.	0.5	20
256	Neurocognition and functional outcome in early-onset schizophrenia and attention-deficit/hyperactivity disorder: A 13-year follow-up.. <i>Neuropsychology</i> , 2011, 25, 25-35.	1.0	51
258	Schizophrenia-Like Attentional Deficits Following Blockade of Prefrontal Cortex GABAA Receptors. <i>Neuropsychopharmacology</i> , 2011, 36, 1703-1713.	2.8	73
259	Efficacy and specificity of Social Cognitive Skills Training for outpatients with psychotic disorders. <i>Journal of Psychiatric Research</i> , 2011, 45, 1113-1122.	1.5	140
260	The treatment of cognitive impairment in schizophrenia. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 99, 245-253.	1.3	153
261	Drug targets for cognitive enhancement in neuropsychiatric disorders. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 99, 130-145.	1.3	120
262	Predictors of Participation in Community Outpatient Psychosocial Rehabilitation in Schizophrenia. <i>Community Mental Health Journal</i> , 2011, 47, 622-627.	1.1	22
263	Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine. <i>Psychopharmacology</i> , 2011, 213, 681-695.	1.5	28

#	ARTICLE	IF	CITATIONS
264	Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. <i>Psychopharmacology</i> , 2011, 214, 843-853.	1.5	36
265	Effects of low-dose d-serine on recognition and working memory in mice. <i>Psychopharmacology</i> , 2011, 218, 461-470.	1.5	79
266	Pattern of neural responses to verbal fluency shows diagnostic specificity for schizophrenia and bipolar disorder. <i>BMC Psychiatry</i> , 2011, 11, 18.	1.1	163
267	Planning and problem-solving training for patients with schizophrenia: a randomized controlled trial. <i>BMC Psychiatry</i> , 2011, 11, 73.	1.1	17
268	L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study. <i>BMC Medicine</i> , 2011, 9, 40.	2.3	21
269	The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: A meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 573-588.	2.9	1,489
271	The Cognitive Genetics of Neuropsychiatric Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 12, 579-613.	0.8	14
272	Impact of Neurocognition on Social and Role Functioning in Individuals at Clinical High Risk for Psychosis. <i>American Journal of Psychiatry</i> , 2011, 168, 806-813.	4.0	164
273	Influence of cognition and symptoms of schizophrenia on IADL performance. <i>Scandinavian Journal of Occupational Therapy</i> , 2011, 18, 180-187.	1.1	27
274	What Is It like to Be a Person with Schizophrenia in the Social World? A First-Person Perspective Study on Schizophrenic Dissociality – Part 1: State of the Art. <i>Psychopathology</i> , 2011, 44, 172-182.	1.1	41
275	The Role of Motivation for Treatment Success. <i>Schizophrenia Bulletin</i> , 2011, 37, S122-S128.	2.3	127
276	Pathways between early visual processing and functional outcome in schizophrenia. <i>Psychological Medicine</i> , 2011, 41, 487-497.	2.7	111
277	Åžizofrenide BiliÅšsel Å°Åšlevler NÅ¼fus ve Klinik Å–zelliklerden Etkilenir mi?. <i>Journal of Microbiology and Biotechnology</i> , 2011, 21, 131-138.	0.9	1
278	Social Cognition as a Mediator Variable Between Neurocognition and Functional Outcome in Schizophrenia: Empirical Review and New Results by Structural Equation Modeling. <i>Schizophrenia Bulletin</i> , 2011, 37, S41-S54.	2.3	404
279	Neurocognitive Predictors of Work Outcome in Recent-Onset Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, S33-S40.	2.3	256
280	At Risk for Psychosis?. <i>Scientific American Mind</i> , 2011, 22, 14-15.	0.0	1
281	Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 795-811.	1.9	8
282	The FDA-NIMH-MATRICES Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?. <i>Schizophrenia Bulletin</i> , 2011, 37, 1209-1217.	2.3	121

#	ARTICLE	IF	CITATIONS
283	The Importance of Cognitive Processes for the Integrative Treatment of Persons with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, S1-S4.	2.3	4
284	Visuospatial attention in schizophrenia: Deficits in broad monitoring.. <i>Journal of Abnormal Psychology</i> , 2012, 121, 119-128.	2.0	49
285	Towards a cognitive resource limitations model of diminished expression in schizotypy.. <i>Journal of Abnormal Psychology</i> , 2012, 121, 109-118.	2.0	46
286	Neurocognitive Predictors of Objective and Subjective Quality of Life in Individuals With Schizophrenia: A Meta-Analytic Investigation. <i>Schizophrenia Bulletin</i> , 2012, 38, 304-315.	2.3	149
287	A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 593-601.	0.7	32
288	The role of cognitive functioning in the outcome of those at clinical high risk for developing psychosis. <i>Epidemiology and Psychiatric Sciences</i> , 2012, 21, 335-342.	1.8	54
289	Can genetics inform the management of cognitive deficits in schizophrenia?. <i>Journal of Psychopharmacology</i> , 2012, 26, 334-348.	2.0	9
290	A Video Ethnography Approach for Linking Naturalistic Behaviors to Research Constructs of Neurocognition in Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, 125-140.	0.9	7
291	Predictors of treatment utilisation at cognitive remediation groups for schizophrenia: The roles of neuropsychological, psychological and clinical variables. <i>Neuropsychological Rehabilitation</i> , 2012, 22, 516-531.	1.0	14
292	Self-recognition Deficits in Schizophrenia Patients With Auditory Hallucinations: A Meta-analysis of the Literature. <i>Schizophrenia Bulletin</i> , 2012, 38, 741-750.	2.3	154
293	Potential therapeutic avenues to tackle social cognition problems in schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 71-81.	1.4	18
294	The Relationship Between Self-Reported Neuropsychological Risk Factors and RBANS Test Performance Among Forensically Committed Psychiatric Inpatients. <i>Applied Neuropsychology Adult</i> , 2012, 19, 279-286.	0.7	13
295	Pseudo-ADHD in a Case of First-Episode Schizophrenia: Diagnostic and Treatment Challenges. <i>Harvard Review of Psychiatry</i> , 2012, 20, 309-317.	0.9	1
296	Less Cognitive and Neurological Deficits in Schizophrenia Patients Carrying Risk Variant in <i>ZNF804A</i> . <i>Neuropsychobiology</i> , 2012, 66, 158-166.	0.9	15
297	Cognitive Remediation and Psychosocial Rehabilitation for Individuals with Severe Mental Illness. <i>Rehabilitation Research and Practice</i> , 2012, 2012, 1-2.	0.5	2
298	Cognitive Remediation for Individuals with Psychosis in a Supported Education Setting: A Pilot Study. <i>Rehabilitation Research and Practice</i> , 2012, 2012, 1-5.	0.5	11
299	Evaluation of Factors Affecting Continuous Performance Test Identical Pairs Version Score of Schizophrenic Patients in a Japanese Clinical Sample. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-5.	0.7	5
300	The puzzle of schizophrenia: Tracking the core role of cognitive deficits. <i>Development and Psychopathology</i> , 2012, 24, 529-536.	1.4	35

#	ARTICLE	IF	CITATIONS
301	Status of Psychotic Disorders in ICD-11. Schizophrenia Bulletin, 2012, 38, 895-898.	2.3	114
303	Efficiency of cognitive rehabilitation with REHACOP in chronic treatment resistant Hispanic patients. NeuroRehabilitation, 2012, 30, 65-74.	0.5	18
304	Predictors of Change in Functional Competence and Functional Behavior After Functional Adaptation Skills Training for Schizophrenia. Journal of Nervous and Mental Disease, 2012, 200, 705-711.	0.5	15
305	Neurofunctional Correlates of Theory of Mind Deficits in Schizophrenia. Current Topics in Medicinal Chemistry, 2012, 12, 2284-2302.	1.0	39
306	Strategies for optimizing medication adherence in schizophrenia. CNS Spectrums, 2012, 17, 31-41.	0.7	2
307	The empirical basis for the practice of cognitive remediation for schizophrenia. Neuropsychiatry, 2012, 2, 101-109.	0.4	3
309	Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia. Schizophrenia Research, 2012, 142, 122-128.	1.1	21
310	REPYFLEC cognitive remediation group training in schizophrenia. Schizophrenia Research, 2012, 142, 137-144.	1.1	26
311	Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients. Schizophrenia Research, 2012, 142, 165-170.	1.1	24
312	Understanding reduced activity in psychosis: the roles of stigma and illness appraisals. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 1685-1693.	1.6	24
313	The relation between mood, cognition and psychosocial functioning in psychiatric disorders. European Neuropsychopharmacology, 2012, 22, S499-S504.	0.3	63
314	The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. European Psychiatry, 2012, 27, 275-280.	0.1	41
315	Cognitive and social cognitive predictors of change in objective versus subjective quality-of-life in rehabilitation for schizophrenia. Psychiatry Research, 2012, 200, 102-107.	1.7	20
316	Is Early Intervention for Psychosis Feasible and Effective?. Psychiatric Clinics of North America, 2012, 35, 613-631.	0.7	68
317	Hypofrontality in schizophrenic patients and its relevance for the choice of antipsychotic medication: An event-related potential study. World Journal of Biological Psychiatry, 2012, 13, 188-199.	1.3	12
318	The Norwegian standardization of the MATRICS (Measurement and Treatment Research to Improve) Tj ETQq1 1 0.784314 rgBT /Overbo Neuropsychology, 2012, 34, 667-677.	0.8	41
319	Increased familiarity of intellectual deficits in early-onset schizophrenia spectrum disorders. World Journal of Biological Psychiatry, 2012, 13, 493-500.	1.3	6
320	Effect of Aripiprazole on Verbal Memory and Fluency in Schizophrenic Patients. CNS Drugs, 2012, 26, 975-982.	2.7	32

#	ARTICLE	IF	CITATIONS
321	Risk Factors for Psychosis: Impaired Social and Role Functioning. <i>Schizophrenia Bulletin</i> , 2012, 38, 1247-1257.	2.3	206
322	NMDA receptors, cognition and schizophrenia – Testing the validity of the NMDA receptor hypofunction hypothesis. <i>Neuropharmacology</i> , 2012, 62, 1401-1412.	2.0	165
323	Auditory orienting and inhibition of return in schizophrenia: A functional magnetic resonance imaging study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 161-168.	2.5	7
324	Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia. <i>Neuroscience Letters</i> , 2012, 522, 151-155.	1.0	53
325	Anterior cingulate cortex activation is related to learning potential on the WCST in schizophrenia patients. <i>Brain and Cognition</i> , 2012, 79, 245-251.	0.8	28
326	Measuring patient-reported outcomes in psychosis: conceptual and methodological review. <i>British Journal of Psychiatry</i> , 2012, 201, 262-267.	1.7	59
327	Classifying psychosis – Challenges and opportunities. <i>International Review of Psychiatry</i> , 2012, 24, 538-548.	1.4	21
328	Transient Inactivation of the Neonatal Ventral Hippocampus Impairs Attentional Set-Shifting Behavior: Reversal with an ± 7 Nicotinic Agonist. <i>Neuropsychopharmacology</i> , 2012, 37, 2476-2486.	2.8	41
329	Cognitive remediation for schizophrenia: current status, biological correlates and predictors of response. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 813-821.	1.4	63
330	A synopsis of recent influential papers published in psychiatric journals (2010–2011) from the Arab World. <i>Asian Journal of Psychiatry</i> , 2012, 5, 175-178.	0.9	5
333	Review of social cognitive treatments for psychosis. <i>Clinical Psychology Review</i> , 2012, 32, 724-740.	6.0	77
334	Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. <i>Schizophrenia Research</i> , 2012, 134, 59-64.	1.1	34
335	The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in Spain. <i>Schizophrenia Research</i> , 2012, 134, 279-284.	1.1	62
336	Inhibition of return and schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2012, 135, 55-61.	1.1	21
337	Mapping hypofrontality during letter fluency task in schizophrenia: A multi-channel near-infrared spectroscopy study. <i>Schizophrenia Research</i> , 2012, 136, 63-69.	1.1	22
338	Plasma total antioxidant status and cognitive impairments in schizophrenia. <i>Schizophrenia Research</i> , 2012, 139, 66-72.	1.1	64
339	Cholinergic pathways and cognition in patients with schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2012, 139, 46-52.	1.1	8
340	Preserved cognitive function is associated with suicidal ideation and single suicide attempts in schizophrenia. <i>Schizophrenia Research</i> , 2012, 140, 232-236.	1.1	81

#	ARTICLE	IF	CITATIONS
341	Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 81-111.	0.9	18
342	Characterization of Neurophysiologic and Neurocognitive Biomarkers for Use in Genomic and Clinical Outcome Studies of Schizophrenia. PLoS ONE, 2012, 7, e39434.	1.1	159
343	Patients with Schizophrenia Fail to Up-Regulate Task-Positive and Down-Regulate Task-Negative Brain Networks: An fMRI Study Using an ICA Analysis Approach. Frontiers in Human Neuroscience, 2012, 6, 149.	1.0	36
344	Support management in schizophrenia: a systematic review of current literature. Patient Intelligence, 2012, , 79.	0.2	1
345	Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Design, Development and Therapy, 2012, 6, 107.	2.0	16
346	Augmentation by escitalopram, but not citalopram or Râ€italopram, of the effects of lowâ€dose risperidone: Behavioral, biochemical, and electrophysiological evidence. Synapse, 2012, 66, 277-290.	0.6	28
347	Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia. Neuropsychopharmacology, 2012, 37, 16-42.	2.8	177
348	Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery, 2012, 11, 141-168.	21.5	960
349	Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nature Reviews Drug Discovery, 2012, 11, 560-579.	21.5	154
350	The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 1077-1086.	1.6	38
351	Processing speed and executive functions predict real-world everyday living skills in adolescents with early-onset schizophrenia. European Child and Adolescent Psychiatry, 2012, 21, 315-326.	2.8	30
352	A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Annals of the New York Academy of Sciences, 2012, 1248, 89-106.	1.8	86
353	Cognitive alterations in patients with nonâ€ffective psychotic disorder and their unaffected siblings and parents. Acta Psychiatrica Scandinavica, 2012, 125, 66-76.	2.2	44
354	Functional outcomes in schizophrenia: Understanding the competence-performance discrepancy. Journal of Psychiatric Research, 2012, 46, 205-211.	1.5	42
355	Do the same factors predict outcome in schizophrenia and non-schizophrenia syndromes after first-episode psychosis? A two-year follow-up study. Journal of Psychiatric Research, 2012, 46, 774-781.	1.5	25
356	Metaâ€analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disorders, 2012, 14, 217-226.	1.1	254
357	Cognitive Impairment Associated with Schizophrenia: A Review of the Humanistic Burden. Advances in Therapy, 2012, 29, 148-162.	1.3	63
358	D1 receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. Psychopharmacology, 2012, 220, 129-141.	1.5	44

#	ARTICLE	IF	CITATIONS
359	The validity of subjective quality of life measures in psychotic patients with severe psychopathology and cognitive deficits: an item response model analysis. <i>Quality of Life Research</i> , 2012, 21, 237-246.	1.5	23
360	The Texture of the Real: Experimentation and Experience in Schizophrenia. <i>Culture, Medicine and Psychiatry</i> , 2012, 36, 154-174.	0.7	2
361	Modulation of NMDA receptor function as a treatment for schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5034-5044.	1.0	28
362	The global cognitive impairment in schizophrenia: Consistent over decades and around the world. <i>Schizophrenia Research</i> , 2013, 150, 42-50.	1.1	472
363	Occupational functioning, symptoms and neurocognition in patients with psychotic disorders: investigating subgroups based on social security status. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 863-874.	1.6	22
364	Cognitive remediation improves cognition and good cognitive performance increases time to relapse – results of a 5 year catamnestic study in schizophrenia patients. <i>BMC Psychiatry</i> , 2013, 13, 184.	1.1	38
365	Functional dysconnectivity in schizophrenia and its relationship to neural synchrony. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 755-765.	1.4	18
366	Twin-based study of the complex interplay between childhood maltreatment, socioeconomic status and adult memory. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 435-440.	1.8	9
367	Neurocognitive individualized training versus social skills individualized training: A randomized trial in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 69-75.	1.1	24
368	Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. <i>Drug Discovery Today</i> , 2013, 18, 1185-1199.	3.2	107
369	Errorless learning and social problem solving ability in schizophrenia: An examination of the compensatory effects of training. <i>Psychiatry Research</i> , 2013, 206, 1-7.	1.7	14
370	Ecological Momentary Assessment of social functioning in schizophrenia: Impact of performance appraisals and affect on social interactions. <i>Schizophrenia Research</i> , 2013, 145, 120-124.	1.1	76
372	Social dysfunction in first-episode psychosis and relations to neurocognition, duration of untreated psychosis and clinical symptoms. <i>Psychiatry Research</i> , 2013, 207, 33-39.	1.7	24
373	Can Repetitive Magnetic Stimulation Improve Cognition in Schizophrenia? Pilot Data from a Randomized Controlled Trial. <i>Biological Psychiatry</i> , 2013, 73, 510-517.	0.7	116
374	Working memory as a predictor of negative symptoms and functional outcome in first episode psychosis. <i>Psychiatry Research</i> , 2013, 206, 8-16.	1.7	58
375	Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 51-57.	1.1	74
376	Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2087-2091.	2.9	67
377	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1376-1382.	1.5	84

#	ARTICLE	IF	CITATIONS
378	WAIS-IV Profile of Cognition in Schizophrenia. <i>Assessment</i> , 2013, 20, 462-473.	1.9	32
379	A primer on the treatment of schizophrenia through repetitive transcranial magnetic stimulation. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1079-1082.	1.4	6
380	Cognitionâ€™emotion interactions in schizophrenia: Emerging evidence on working memory load and implicit facial-affective processing. <i>Cognition and Emotion</i> , 2013, 27, 875-899.	1.2	10
381	A synopsis of recent influential papers published in psychiatric journals from the Arab world (2012). <i>Asian Journal of Psychiatry</i> , 2013, 6, 606-608.	0.9	2
382	Using joint ICA to link function and structure using MEG and DTI in schizophrenia. <i>NeuroImage</i> , 2013, 83, 418-430.	2.1	47
383	Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release. <i>Neuroscience</i> , 2013, 255, 55-67.	1.1	20
384	Cognitive deficits and its relation with psychopathology and global functioning in first episode schizophrenia. <i>Asian Journal of Psychiatry</i> , 2013, 6, 537-543.	0.9	25
385	The potential role of dopamine D3 receptor neurotransmission in cognition. <i>European Neuropsychopharmacology</i> , 2013, 23, 799-813.	0.3	153
386	Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia. <i>Schizophrenia Research</i> , 2013, 146, 238-243.	1.1	25
388	Efficacy of social cognition remediation programs targeting facial affect recognition deficits in schizophrenia: A review and consideration of high-risk samples and sex differences. <i>Psychiatry Research</i> , 2013, 206, 125-139.	1.7	41
390	Self-efficacy and functional status in schizophrenia: Relationship to insight, cognition and negative symptoms. <i>Schizophrenia Research</i> , 2013, 145, 69-74.	1.1	40
391	Functional profile of mental health consumers assessed by occupational therapists: Level of independence and associations with functional cognition. <i>Psychiatry Research</i> , 2013, 208, 29-32.	1.7	10
392	The relative contribution of neurocognition and social cognition to 6-month vocational outcomes following Individual Placement and Support in first-episode psychosis. <i>Schizophrenia Research</i> , 2013, 150, 136-143.	1.1	52
393	Cognitive Performance of Individuals With Schizophrenia Across Seven Decades: A Study Using the MATRICS Consensus Cognitive Battery. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 108-118.	0.6	68
394	Cognitive regulation of negative affect in schizophrenia and bipolar disorder. <i>Psychiatry Research</i> , 2013, 208, 21-28.	1.7	61
395	Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. <i>Schizophrenia Research</i> , 2013, 147, 58-67.	1.1	41
396	P.3.b.028 Transcultural study of clinical and psychosocial aspects of schizophrenia: comparison of patients in Armenia and Belarus. <i>European Neuropsychopharmacology</i> , 2013, 23, S445-S446.	0.3	0
397	A brief cognitiveâ€™behavioural social skills training for stabilised outpatients with schizophrenia: A preliminary study. <i>Schizophrenia Research</i> , 2013, 143, 327-336.	1.1	52

#	ARTICLE	IF	CITATIONS
398	Social cognition and interaction training for patients with stable schizophrenia in Chinese community settings. <i>Psychiatry Research</i> , 2013, 210, 751-755.	1.7	44
399	Predictors of medication adherence in patients with schizophrenia and bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 23-33.	2.2	123
400	A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia. <i>Schizophrenia Research</i> , 2013, 144, 129-135.	1.1	19
401	Negative Symptoms and Executive Function in Schizophrenia: Does Their Relationship Change with Illness Duration?. <i>Psychopathology</i> , 2013, 46, 241-248.	1.1	26
402	Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: Relevance to DSM-5. <i>Schizophrenia Research</i> , 2013, 150, 15-20.	1.1	165
403	Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological "minefield". <i>Cell and Tissue Research</i> , 2013, 354, 247-257.	1.5	10
404	Association between DBH 19 bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients. <i>Schizophrenia Research</i> , 2013, 147, 236-240.	1.1	19
405	A Test of the Cognitive Self-Medication Hypothesis of Tobacco Smoking in Schizophrenia. <i>Biological Psychiatry</i> , 2013, 74, 436-443.	0.7	72
406	Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different. <i>Psychological Medicine</i> , 2013, 43, 2535-2545.	2.7	28
407	Psychotic disorders in ICD-11. <i>Asian Journal of Psychiatry</i> , 2013, 6, 263-265.	0.9	31
408	Theory of Mind intervention for outpatients with schizophrenia. <i>Neuropsychological Rehabilitation</i> , 2013, 23, 383-400.	1.0	47
409	The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. <i>Neuropharmacology</i> , 2013, 64, 185-190.	2.0	15
410	Egis-11150: A candidate antipsychotic compound with procognitive efficacy in rodents. <i>Neuropharmacology</i> , 2013, 64, 254-263.	2.0	17
411	Inhibition of GABA synthesis in the prefrontal cortex increases locomotor activity but does not affect attention in the 5-choice serial reaction time task. <i>Neuropharmacology</i> , 2013, 65, 39-47.	2.0	30
412	Cognitive function in schizophrenia: insights from intelligence research. <i>British Journal of Psychiatry</i> , 2013, 203, 161-162.	1.7	20
413	The Role of the Major Histocompatibility Complex Region in Cognition and Brain Structure: A Schizophrenia GWAS Follow-Up. <i>American Journal of Psychiatry</i> , 2013, 170, 877-885.	4.0	60
414	Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 2181-2194.	1.0	103
415	Empirically Based Psychosocial Therapies for Schizophrenia: The Disconnection between Science and Practice. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-8.	0.7	7

#	ARTICLE	IF	CITATIONS
416	Brain vs Behavior: An Effect Size Comparison of Neuroimaging and Cognitive Studies of Genetic Risk for Schizophrenia. Schizophrenia Bulletin, 2013, 39, 518-526.	2.3	83
417	Testing sensory and cognitive explanations of the antisaccade deficit in schizophrenia.. Journal of Abnormal Psychology, 2013, 122, 1111-1120.	2.0	12
418	Combining Computerized Social Cognitive Training with Neuroplasticity-Based Auditory Training in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2013, 7, 78-86A.	1.4	56
419	Neuropsychological and neuroanatomical sequelae of chronic non-malignant pain and opioid analgesia. NeuroRehabilitation, 2013, 33, 343-366.	0.5	19
420	Does cognitive remediation for schizophrenia improve functional outcomes?. Current Opinion in Psychiatry, 2013, 26, 151-157.	3.1	167
421	Cognitive impairment and neurological soft signs in an Egyptian sample of schizophrenia patients. Middle East Current Psychiatry, 2013, 20, 14-21.	0.5	1
422	Longitudinal Relationships Between Neurocognition, Theory of Mind, and Community Functioning in Outpatients With Serious Mental Illness. Journal of Nervous and Mental Disease, 2013, 201, 786-794.	0.5	12
423	Neurocognitive Functioning in Schizophrenia and during the Early Phases of Psychosis: Targeting Cognitive Remediation Interventions. BioMed Research International, 2013, 2013, 1-8.	0.9	19
424	A self administered executive functions ecological questionnaire (the Behavior Rating Inventory of) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 Mental Illness, 2013, 5, 4.	0.8	13
425	Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. Psychological Medicine, 2013, 43, 1161-1173.	2.7	87
426	Neurocognitive phenomics: examining the genetic basis of cognitive abilities. Psychological Medicine, 2013, 43, 2027-2036.	2.7	13
427	Quetiapine and flupentixol differentially improve anterior cingulate cortex function in schizophrenia patients: an event-related potential study. International Journal of Neuropsychopharmacology, 2013, 16, 1911-1925.	1.0	9
428	Current Trends in the Empirical Study of Cognitive Remediation for Schizophrenia. Canadian Journal of Psychiatry, 2013, 58, 311-318.	0.9	37
429	Análise qualitativa do impacto do programa de treino metacognitivo e da cognição social em pessoas com Esquizofrenia. Estudos De Psicologia (Natal), 2013, 18, 559-568.	0.0	0
430	Cognition as a central illness feature in schizophrenia. , 0, , 1-23.		4
432	Neuropsychological and Socio-Occupational Functioning in Young Psychiatric Outpatients: A Longitudinal Investigation. PLoS ONE, 2013, 8, e58176.	1.1	91
433	Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?. Frontiers in Psychiatry, 2013, 4, 157.	1.3	35
434	Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation. Frontiers in Behavioral Neuroscience, 2013, 7, 180.	1.0	22

#	ARTICLE	IF	CITATIONS
435	Acute nicotine improves social decision-making in non-smoking but not in smoking schizophrenia patients. <i>Frontiers in Neuroscience</i> , 2013, 7, 197.	1.4	13
436	The multi-faceted, "global" cognitive impairment profile in schizophrenia. , 2013, , 24-49.		1
438	Treatment-Resistant Schizophrenia: Prevalence and Risk Factors. , 0, , .		3
439	A self administered executive functions ecological questionnaire (the Behavior Rating Inventory of Tj ETQq1 1 0.784314 rgBT /Overlock Mental Illness, 2013, 5, 14-16.	0.8	1
440	Transcranial Direct Current Stimulation to Enhance Cognition and Functioning in Schizophrenia. <i>Journal of Novel Physiotherapies</i> , 2014, 04, .	0.1	1
441	Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System. <i>Frontiers in Psychiatry</i> , 2014, 5, 32.	1.3	37
442	MK-801 Impairs Cognitive Coordination on a Rotating Arena (Carousel) and Contextual Specificity of Hippocampal Immediate-Early Gene Expression in a Rat Model of Psychosis. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 75.	1.0	16
443	A virtual reality task based on animal research " spatial learning and memory in patients after the first episode of schizophrenia. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 157.	1.0	34
444	Serotonergic and dopaminergic modulation of cortico-striatal circuit in executive and attention deficits induced by NMDA receptor hypofunction in the 5-choice serial reaction time task. <i>Frontiers in Neural Circuits</i> , 2014, 8, 58.	1.4	46
445	RC2S: A Cognitive Remediation Program to Improve Social Cognition in Schizophrenia and Related Disorders. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 400.	1.0	58
446	Multisensory stimuli elicit altered oscillatory brain responses at gamma frequencies in patients with schizophrenia. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 788.	1.0	12
447	The Ultimatum Game and the brain: A meta-analysis of neuroimaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 47, 549-558.	2.9	152
448	Positive and negative subclinical symptoms and MCCB performance in non-psychiatric controls. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 175-179.	0.7	9
449	Enhancing and Promoting Recovery in Attentionally Impaired People Diagnosed with Schizophrenia: Results From a Randomized Controlled Trial of Attention Shaping in a Partial Hospital Program. <i>American Journal of Psychiatric Rehabilitation</i> , 2014, 17, 272-305.	0.7	8
450	Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches. <i>American Journal of Psychiatric Rehabilitation</i> , 2014, 17, 225-253.	0.7	46
451	Cognitive-Behavioral Therapy for Medication-Resistant Psychosis: A Meta-Analytic Review. <i>Psychiatric Services</i> , 2014, 65, 874-880.	1.1	178
452	Working Memory Training in Schizophrenia and Healthy Populations. <i>Behavioral Sciences (Basel)</i> , Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	27
453	Impaired GABAergic Inhibition in the Prefrontal Cortex of Early Postnatal Phencyclidine (PCP)-Treated Rats. <i>Cerebral Cortex</i> , 2014, 24, 2522-2532.	1.6	21

#	ARTICLE	IF	CITATIONS
454	Stable Schizophrenia Patients Learn Equally Well as Age-Matched Controls and Better than Elderly Controls in Two Sensorimotor Rotary Pursuit Tasks. <i>Frontiers in Psychiatry</i> , 2014, 5, 165.	1.3	7
455	Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. <i>BMC Psychiatry</i> , 2014, 14, 335.	1.1	74
456	Perception of the influence of environmental factors in the use of electronic planning devices in adults with cognitive disabilities. <i>Disability and Rehabilitation: Assistive Technology</i> , 2016, 11, 1-8.	1.3	11
457	Brief report: The impact of alcohol and cannabis misuse on cognition among individuals with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 160-163.	0.7	2
458	Longitudinal Evaluation of the Psychomotor Syndrome in Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014, 26, 359-368.	0.9	14
459	Performance-Based Empathy Mediates the Influence of Working Memory on Social Competence in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 824-834.	2.3	69
460	Functional polymorphism (C^C-824T) of the tyrosine hydroxylase gene affects IQ in schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 456-462.	1.0	22
461	Proactive coping in schizophrenia: examining the impact of neurocognitive variables. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2014, 21, 471-476.	1.2	0
462	Cognitive impairments in psychotic disorders: common mechanisms and measurement. <i>World Psychiatry</i> , 2014, 13, 224-232.	4.8	124
463	Cancer care for individuals with schizophrenia. <i>Cancer</i> , 2014, 120, 323-334.	2.0	134
464	Revisions and refinements of the diagnosis of schizophrenia in DSM-5. <i>Clinical Psychology: Science and Practice</i> , 2014, 21, 236-244.	0.6	5
465	The MATRICS Consensus Cognitive Battery (MCCB): Performance and functional correlates. <i>Psychiatry Research</i> , 2014, 220, 1094-1101.	1.7	22
466	Validation of the Persian version of the Brief Assessment of Cognition in Schizophrenia in patients with schizophrenia and healthy controls. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 160-166.	1.0	17
467	A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 1433-1442.	2.3	46
468	Improving Outcomes for Youth with ADHD: A Conceptual Framework for Combined Neurocognitive and Skill-Based Treatment Approaches. <i>Clinical Child and Family Psychology Review</i> , 2014, 17, 368-384.	2.3	78
469	Late-onset schizophrenia. <i>Current Opinion in Psychiatry</i> , 2014, 27, 173-178.	3.1	53
470	Multifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy. <i>Journal of ECT</i> , 2014, 30, 165-176.	0.3	98
471	Effect of S-ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression. <i>Journal of ECT</i> , 2014, 30, 176.	0.3	1

#	ARTICLE	IF	CITATIONS
472	Metabotropic Glutamate Receptor 2 Activators. Topics in Medicinal Chemistry, 2014, , 101-142.	0.4	4
473	Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychological Medicine, 2014, 44, 61-69.	2.7	41
474	Differential Effects of Common Variants in<i>SCN2A</i> on General Cognitive Ability, Brain Physiology, and messenger RNA Expression in Schizophrenia Cases and Control Individuals. JAMA Psychiatry, 2014, 71, 647.	6.0	33
475	Neurocognitive Functioning of Individuals With Schizophrenia: Using and Not Using Drugs. Schizophrenia Bulletin, 2014, 40, 856-867.	2.3	26
476	The relationship between IQ and performance on the MATRICS consensus cognitive battery. Schizophrenia Research: Cognition, 2014, 1, 96-100.	0.7	26
477	INECO Frontal Screening: an Instrument to assess Executive Dysfunction in Schizophrenia. Spanish Journal of Psychology, 2014, 17, E19.	1.1	7
478	Enhanced distraction by magnocellular salience signals in schizophrenia. Neuropsychologia, 2014, 56, 359-366.	0.7	15
479	The evolution of illness phases in schizophrenia: A non-parametric item response analysis of the Positive and Negative Syndrome Scale. Schizophrenia Research: Cognition, 2014, 1, 53-89.	0.7	5
480	Prospective memory predicts the level of community living skills in schizophrenia. Psychiatry Research, 2014, 219, 86-91.	1.7	12
481	Cognition in schizophrenia: Past, present, and future. Schizophrenia Research: Cognition, 2014, 1, e1-e9.	0.7	181
482	A longitudinal examination of the moderating effects of symptoms on the relationship between functional competence and real world functional performance in Schizophrenia. Schizophrenia Research: Cognition, 2014, 1, 90-95.	0.7	36
483	Transient inactivation of the ventral hippocampus in neonatal rats impairs the mesolimbic regulation of prefrontal glutamate release inÂadulthood. Neuropharmacology, 2014, 84, 19-30.	2.0	4
484	Modafinil combined with cognitive training is associated with improved learning in healthy volunteers â€“ A randomised controlled trial. European Neuropsychopharmacology, 2014, 24, 529-539.	0.3	35
485	In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia. Psychopharmacology, 2014, 231, 3151-3167.	1.5	37
486	Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats. Psychopharmacology, 2014, 231, 673-683.	1.5	31
487	Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiology and Behavior, 2014, 129, 194-198.	1.0	49
488	A virtual reality-integrated program for improving social skills in patients with schizophrenia: A pilot study. Journal of Behavior Therapy and Experimental Psychiatry, 2014, 45, 81-89.	0.6	128
490	Brain Stimulation in the Treatment of Late-Life Severe Mental Illness Other than Unipolar Nonpsychotic Depression. American Journal of Geriatric Psychiatry, 2014, 22, 216-240.	0.6	25

#	ARTICLE	IF	CITATIONS
491	Comprehension of metaphors in patients with schizophrenia-spectrum disorders. <i>Comprehensive Psychiatry</i> , 2014, 55, 928-937.	1.5	47
492	The nicotinic receptor as a target for cognitive enhancement in schizophrenia: Barking up the wrong tree?. <i>Psychopharmacology</i> , 2014, 231, 543-550.	1.5	20
493	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	4.8	346
494	Antidepressants for cognitive impairment in schizophrenia – A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2014, 159, 385-394.	1.1	48
495	A pilot study to measure cognitive impairment in patients with severe schizophrenia with the Montreal Cognitive Assessment (MoCA). <i>Schizophrenia Research</i> , 2014, 158, 151-155.	1.1	51
496	The influence of metacognitive training on delusion severity and metacognitive ability in schizophrenia. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2014, 21, 841-847.	1.2	28
497	Psychotic symptoms, cognition and affect as predictors of psychosocial problems and functional change in first-episode psychosis. <i>Schizophrenia Research</i> , 2014, 158, 113-119.	1.1	37
498	Adolescents Are Like Adults (Sort of): Psychosocial Interventions for Adolescents With or Vulnerable to Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 833-834.	0.3	6
499	Cognitive Remediation Therapy in Adolescents With Early-Onset Schizophrenia: A Randomized Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 859-868.	0.3	57
500	Neurocognitive Pattern Analysis Reveals Classificatory Hierarchy of Attention Deficits in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 878-885.	2.3	16
501	A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2014, 158, 230-235.	1.1	52
502	Cognitive Remediation for Schizophrenia: A Review of Recent Findings. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 121-133.	0.7	12
503	Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices. <i>BMC Neurology</i> , 2014, 14, 78.	0.8	12
504	MATRICES cognitive consensus battery (MCCB) performance in children, adolescents, and young adults. <i>Schizophrenia Research</i> , 2014, 152, 223-228.	1.1	20
505	Self-conscious emotions ^{x3} role in functional outcomes within clinical populations. <i>Psychiatry Research</i> , 2014, 216, 17-23.	1.7	5
506	Daily activity patterns in remitted first-episode schizophrenia. <i>Comprehensive Psychiatry</i> , 2014, 55, 1182-1187.	1.5	7
507	Investigation of the role of the jumping-to-conclusions bias for short-term functional outcome in schizophrenia. <i>Psychiatry Research</i> , 2014, 218, 341-347.	1.7	22
508	Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 83-91.	2.5	15

#	ARTICLE	IF	CITATIONS
509	Impaired cognitive control mediates the relationship between cortical thickness of the superior frontal gyrus and role functioning in schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 358-364.	1.1	48
510	Subjects at Ultra High Risk for psychosis have "heterogeneous" intellectual functioning profile: A multiple-case study. <i>Schizophrenia Research</i> , 2014, 152, 415-420.	1.1	16
511	A pilot study on the effects of cognitive remediation on hemodynamic responses in the prefrontal cortices of patients with schizophrenia: A multi-channel near-infrared spectroscopy study. <i>Schizophrenia Research</i> , 2014, 153, 87-95.	1.1	27
512	The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. <i>Reviews in the Neurosciences</i> , 2014, 25, 367-82.	1.4	29
513	Pharmacotherapy of cognitive deficits in schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 142-156.	0.7	17
514	Cognitive remediation for individuals with psychosis in a supported education setting: A randomized controlled trial. <i>Schizophrenia Research</i> , 2014, 157, 90-98.	1.1	29
515	The role of dysfunctional attitudes in models of negative symptoms and functioning in schizophrenia. <i>Schizophrenia Research</i> , 2014, 157, 182-189.	1.1	50
516	Stability and change in symptoms, cognition, and community outcome in schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 435-439.	1.1	17
517	Cognition, Function, and Disability in Patients with Schizophrenia: A Review of Longitudinal Studies. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 13-17.	0.9	111
518	Preserved, deteriorated, and premorbidly impaired patterns of intellectual ability in schizophrenia. <i>Neuropsychology</i> , 2014, 28, 353-358.	1.0	21
520	Environmental Adaptations Improve Everyday Action in Schizophrenia. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 319-329.	1.2	2
521	Does chronic nicotine consumption influence visual backward masking in schizophrenia and schizotypy?. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 93-99.	0.7	7
522	The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. <i>NPJ Schizophrenia</i> , 2015, 1, 15043.	2.0	60
523	Functional Outcome in Patients With Schizophrenia: The Concept and Measurement. <i>Activitas Nervosa Superior</i> , 2015, 57, 1-11.	0.4	8
524	Neurophysiological evidence for diminished monitoring of own, but intact monitoring of other's errors in schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 220-226.	1.7	10
525	Genetics, sleep and memory: a recall-by-genotype study of ZNF804A variants and sleep neurophysiology. <i>BMC Medical Genetics</i> , 2015, 16, 96.	2.1	10
526	Neurocognitive predictors of performance-based functional capacity in bipolar disorder. <i>Journal of Neuropsychology</i> , 2015, 9, 159-171.	0.6	17
527	Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy. <i>International Journal of Mental Health Systems</i> , 2015, 9, 37.	1.1	14

#	ARTICLE	IF	CITATIONS
528	Enhancing assertive community treatment with cognitive behavioral social skills training for schizophrenia: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 438.	0.7	13
529	MK-801-induced deficits in social recognition in rats. <i>Behavioural Pharmacology</i> , 2015, 26, 748-765.	0.8	35
530	Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. <i>International Journal of Molecular Sciences</i> , 2015, 16, 24475-24489.	1.8	24
531	Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. <i>Nutrients</i> , 2015, 7, 8767-8782.	1.7	22
532	Impaired Verbal Learning Is Associated with Larger Caudate Volumes in Early Onset Schizophrenia Spectrum Disorders. <i>PLoS ONE</i> , 2015, 10, e0130435.	1.1	9
533	Metacognition-augmented cognitive remediation training reduces jumping to conclusions and overconfidence but not neurocognitive deficits in psychosis. <i>Frontiers in Psychology</i> , 2015, 6, 1048.	1.1	27
534	Editorial: Cognition Across the Psychiatric Disorder Spectrum: From Mental Health to Clinical Diagnosis. <i>Frontiers in Psychiatry</i> , 2015, 6, 110.	1.3	3
535	The Effectiveness and Applicability of Compensatory Cognitive Training for Japanese Patients with Schizophrenia: A Pilot Study. <i>Advances in Psychiatry</i> , 2015, 2015, 1-12.	0.4	1
536	Top-Down Computerized Cognitive Remediation in Schizophrenia: A Case Study of an Individual with Impairment in Verbal Fluency. <i>Case Reports in Psychiatry</i> , 2015, 2015, 1-10.	0.2	3
537	Cognitive Performance associated to functional outcomes in stable outpatients with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 146-158.	0.7	19
538	The muscarinic system, cognition and schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 393-402.	2.9	81
539	Effects of chronic inhibition of GABA synthesis on attention and impulse control. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 135, 97-104.	1.3	20
540	Cognitive Remediation in a Residential Rehabilitation Setting. <i>Psychiatric Annals</i> , 2015, 45, 126-130.	0.1	1
541	Fronto-parietal and cingulo-opercular network integrity and cognition in health and schizophrenia. <i>Neuropsychologia</i> , 2015, 73, 82-93.	0.7	160
542	In Search of Multimodal Neuroimaging Biomarkers of Cognitive Deficits in Schizophrenia. <i>Biological Psychiatry</i> , 2015, 78, 794-804.	0.7	158
543	Spatial navigation in virtual reality " From animal models towards schizophrenia: Spatial cognition tests based on animal research. , 2015, , .		1
544	Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. <i>European Psychiatry</i> , 2015, 30, 995-1001.	0.1	35
545	A dimensional comparison between delusional disorder, schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , 2015, 169, 248-254.	1.1	27

#	ARTICLE	IF	CITATIONS
546	Neuropsychological profile in adult schizophrenia measured with the CMINDS. <i>Psychiatry Research</i> , 2015, 230, 826-834.	1.7	45
547	Unraveling Psychomotor Slowing in Bipolar Disorder. <i>Neuropsychobiology</i> , 2015, 71, 234-240.	0.9	5
548	Source retrieval is not properly differentiated from object retrieval in early schizophrenia: An fMRI study using virtual reality. <i>NeuroImage: Clinical</i> , 2015, 7, 336-346.	1.4	16
549	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 161, 351-356.	1.1	32
550	Persistence of effectiveness of cognitive remediation interventions in schizophrenia: A 1-year follow-up study. <i>Schizophrenia Research</i> , 2015, 161, 403-406.	1.1	21
551	Social skills training and computer-assisted cognitive remediation in schizophrenia. <i>Schizophrenia Research</i> , 2015, 162, 35-41.	1.1	46
552	Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 131, 119-129.	1.3	31
554	Telencephalic neurocircuitry and synaptic plasticity in rodent spatial learning and memory. <i>Brain Research</i> , 2015, 1621, 294-308.	1.1	14
555	Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. <i>Journal of Psychopharmacology</i> , 2015, 29, 197-211.	2.0	36
556	Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice. <i>Behavioural Brain Research</i> , 2015, 282, 165-175.	1.2	73
557	Sensory modulation and daily-life participation in people with schizophrenia. <i>Comprehensive Psychiatry</i> , 2015, 58, 130-137.	1.5	19
558	In Vivo Pharmacological Characterization of TAK-063, a Potent and Selective Phosphodiesterase 10A Inhibitor with Antipsychotic-Like Activity in Rodents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 471-479.	1.3	49
559	The Adults and Older Adults Functional Assessment Inventory. <i>Research on Aging</i> , 2015, 37, 787-814.	0.9	16
560	mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching/non-matching-to-sample task. <i>Psychopharmacology</i> , 2015, 232, 251-258.	1.5	23
561	Maximizing the effect of an $\alpha 7$ nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits. <i>Brain Research</i> , 2015, 1611, 8-17.	1.1	11
562	An electrophysiological insight into visual attention mechanisms underlying schizotypy. <i>Biological Psychology</i> , 2015, 109, 206-221.	1.1	10
563	Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. <i>Schizophrenia Research</i> , 2015, 165, 76-82.	1.1	150
564	Broad spectrum psychiatric comorbidity is associated with better executive functioning in an inpatient sample of individuals with schizophrenia. <i>Comprehensive Psychiatry</i> , 2015, 60, 47-52.	1.5	3

#	ARTICLE	IF	CITATIONS
565	Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to N-Desmethylclozapine. <i>American Journal of Psychiatry</i> , 2015, 172, 579-585.	4.0	63
566	Validity and reliability of the Spanish version of the Personal and Social Performance scale in adolescents with schizophrenia. <i>Schizophrenia Research</i> , 2015, 164, 176-180.	1.1	6
568	Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. <i>Schizophrenia Research</i> , 2015, 164, 115-121.	1.1	13
569	Gene-environment interaction of reelin and stress in cognitive behaviours in mice: Implications for schizophrenia. <i>Behavioural Brain Research</i> , 2015, 287, 304-314.	1.2	34
570	The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties. <i>Psychiatric Quarterly</i> , 2015, 86, 435-447.	1.1	15
571	Examining the Psychosis Continuum. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 80-89.	0.6	92
572	Luria revisited: cognitive research in schizophrenia, past implications and future challenges. <i>Philosophy, Ethics, and Humanities in Medicine</i> , 2015, 10, 4.	0.7	17
573	One-Year Randomized Controlled Trial and Follow-Up of Integrated Neurocognitive Therapy for Schizophrenia Outpatients. <i>Schizophrenia Bulletin</i> , 2015, 41, 604-616.	2.3	81
574	Facial affect processing deficits in schizophrenia: A meta-analysis of antipsychotic treatment effects. <i>Journal of Psychopharmacology</i> , 2015, 29, 224-229.	2.0	24
575	The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial. <i>Schizophrenia Bulletin</i> , 2015, 41, 859-868.	2.3	164
576	Qualitative and quantitative aspects of information processing in first psychosis: Latent class analyses in patients, at-risk subjects, and controls. <i>Psychophysiology</i> , 2015, 52, 585-593.	1.2	2
577	Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia. <i>Neuropsychopharmacology</i> , 2015, 40, 2705-2714.	2.8	68
578	UPSA-M: Feasibility and initial validity of a mobile application of the UCSD Performance-Based Skills Assessment. <i>Schizophrenia Research</i> , 2015, 164, 187-192.	1.1	25
579	Resting fMRI measures are associated with cognitive deficits in schizophrenia assessed by the MATRICS consensus cognitive battery. , 2015, , .		0
580	From hospital admission to independent living: Is prediction possible?. <i>Psychiatry Research</i> , 2015, 226, 499-506.	1.7	3
581	Functional outcome in major psychiatric disorders and associated clinical and psychosocial variables: A potential cross-diagnostic phenotype for further genetic investigations?. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 237-248.	1.3	17
583	Role for the M ₁ Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1683-1695.	1.7	48
584	Cognitive course in first-episode psychosis and clinical correlates: A 4 year longitudinal study using the MATRICS Consensus Cognitive Battery. <i>Schizophrenia Research</i> , 2015, 169, 101-108.	1.1	26

#	ARTICLE	IF	CITATIONS
585	Converging models of schizophrenia – Network alterations of prefrontal cortex underlying cognitive impairments. <i>Progress in Neurobiology</i> , 2015, 134, 178-201.	2.8	71
586	EEG correlates of impaired self-other integration during joint-task performance in schizophrenia. <i>Social Cognitive and Affective Neuroscience</i> , 2015, 10, 1365-1372.	1.5	6
587	Differences in cognitive function and daily living skills between early- and late-stage schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 245-251.	1.2	4
588	Exploring cognitive heterogeneity in first-episode psychosis: What cluster analysis can reveal. <i>Psychiatry Research</i> , 2015, 229, 819-827.	1.7	48
589	Increased Cerebral Blood Flow Associated with Better Response Inhibition in Bipolar Disorder. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 105-115.	1.2	19
590	Psychotic disorder and educational achievement: a family-based analysis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 1511-1518.	1.6	20
592	Therapeutic Potential of $\alpha 7$ Nicotinic Acetylcholine Receptors. <i>Pharmacological Reviews</i> , 2015, 67, 1025-1073.	7.1	123
593	Metamemory in patients with schizophrenia measured by the feeling of knowing. <i>Psychiatry Research</i> , 2015, 230, 511-516.	1.7	5
594	Conceptual disorganization weakens links in cognitive pathways: Disentangling neurocognition, social cognition, and metacognition in schizophrenia. <i>Schizophrenia Research</i> , 2015, 169, 153-158.	1.1	33
595	A Meta-Analysis of Autobiographical Memory Studies in Schizophrenia Spectrum Disorder. <i>Schizophrenia Bulletin</i> , 2016, 42, sbv099.	2.3	79
596	Memory systems in schizophrenia: Modularity is preserved but deficits are generalized. <i>Schizophrenia Research</i> , 2015, 168, 223-230.	1.1	7
597	Executive dysfunction in schizophrenia and its association with mentalizing abilities. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2015, 8, 119-129.	0.2	6
598	Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 304-309.	1.1	26
599	$\alpha 7$ nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: Implications for cognitive dysfunction in schizophrenia. <i>Neuropharmacology</i> , 2015, 90, 42-52.	2.0	20
600	High Rates of Obstructive Sleep Apnea Symptoms Among Patients With Schizophrenia. <i>Psychosomatics</i> , 2015, 56, 59-66.	2.5	31
601	La funciÃ³n ejecutiva en la esquizofrenia y su asociaciÃ³n con las habilidades cognitivas sociales (mentalistas). <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2015, 8, 119-129.	1.0	11
602	Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 900-908.	2.3	17
603	Different Effects of Cigarette Smoking on Neuropsychological Performance in Psychiatric Disorders. , 2016, , 305-316.		0

#	ARTICLE	IF	CITATIONS
604	Reduced Prepulse Inhibition as a Biomarker of Schizophrenia. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 202.	1.0	161
605	Cognitive Performance and Long-Term Social Functioning in Psychotic Disorder: A Three-Year Follow-Up Study. <i>PLoS ONE</i> , 2016, 11, e0151299.	1.1	24
606	The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia. <i>PLoS ONE</i> , 2016, 11, e0159996.	1.1	28
607	Improving Facial Emotion Recognition in Schizophrenia: a Controlled Study Comparing Specific and Attentional Focused Cognitive Remediation. <i>Frontiers in Psychiatry</i> , 2016, 7, 105.	1.3	28
608	Admission Volume and Quality of Mental Health Care Among Danish Patients With Recently Diagnosed Schizophrenia. <i>Psychiatric Services</i> , 2016, 67, 536-542.	1.1	6
609	Higher prevalence of dementia in patients with schizophrenia: A nationwide population-based study. <i>Asia-Pacific Psychiatry</i> , 2016, 8, 145-153.	1.2	13
610	Revisiting the validity of measures of social cognitive bias in schizophrenia: Additional results from the Social Cognition Psychometric Evaluation (SCOPE) study. <i>British Journal of Clinical Psychology</i> , 2016, 55, 441-454.	1.7	39
611	Episodic foresight and schizophrenia. <i>British Journal of Clinical Psychology</i> , 2016, 55, 107-122.	1.7	18
612	The $\alpha 7$ Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study. <i>Neuropsychopharmacology</i> , 2016, 41, 2893-2902.	2.8	29
613	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2016, 9, 219-227.	0.2	6
614	Factors discriminating employment status following in-patient evaluation among persons with schizophrenia. <i>Work</i> , 2016, 53, 469-478.	0.6	2
615	Participation in daily life of people with schizophrenia in comparison to the general population. <i>Canadian Journal of Occupational Therapy</i> , 2016, 83, 297-305.	0.8	15
616	A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex. <i>Journal of Neuroscience</i> , 2016, 36, 12570-12585.	1.7	17
617	Acetylcholinergic Nicotinic Receptors as Pharmacological Targets for Cognitive Enhancement: Emerging Evidence from Psychosis Populations. , 2016, , 707-730.		0
618	Relative and Absolute Reliabilities of the Conners [™] Continuous Performance Test II in Schizophrenia. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 769-779.	0.3	4
619	Visual mismatch negativity (vMMN): A review and meta-analysis of studies in psychiatric and neurological disorders. <i>Cortex</i> , 2016, 80, 76-112.	1.1	107
620	An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia. <i>Psychiatry Research</i> , 2016, 236, 47-52.	1.7	17
621	Neurocognition and occupational functioning in schizophrenia spectrum disorders: The MATRICS Consensus Cognitive Battery (MCCB) and workplace assessments. <i>Schizophrenia Research</i> , 2016, 170, 143-149.	1.1	22

#	ARTICLE	IF	CITATIONS
622	Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder. <i>BMC Psychiatry</i> , 2016, 16, 5.	1.1	8
623	Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study. <i>Schizophrenia Research</i> , 2016, 175, 57-63.	1.1	61
624	Neuroscience-informed auditory training in schizophrenia: A final report of the effects on cognition and serum brain-derived neurotrophic factor. <i>Schizophrenia Research: Cognition</i> , 2016, 3, 1-7.	0.7	47
625	Î-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 923-939.	0.6	15
626	Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. <i>Psychopharmacology</i> , 2016, 233, 2399-2410.	1.5	23
627	Lifetime suicide intent, executive function and insight in schizophrenia and schizoaffective disorders. <i>Schizophrenia Research</i> , 2016, 178, 12-16.	1.1	22
628	Successful evaluation of cognitive function and the nature of cognitive deficits among people with schizophrenia in clinical rehabilitation settings. <i>Australasian Psychiatry</i> , 2016, 24, 342-346.	0.4	3
629	Metacognition as a Mediating Variable Between Neurocognition and Functional Outcome in First Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw128.	2.3	36
630	Association of the <i>brain-derived neurotrophic factor</i> Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. <i>European Psychiatry</i> , 2016, 38, 61-69.	0.1	17
631	Biomarcadores sanguíneos diferenciales de las dimensiones psicopatológicas de la esquizofrenia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 219-227.	1.0	21
632	The Cognitive Assessment Interview: A comparative study in first episode and chronic patients with psychosis. <i>Schizophrenia Research</i> , 2016, 178, 80-85.	1.1	8
633	The relationship between change in cognition and change in functional ability in schizophrenia during cognitive and psychosocial rehabilitation. <i>Psychiatry Research</i> , 2016, 244, 145-150.	1.7	26
634	The effects of aerobic exercise on cognition in schizophrenia: A 3-month follow-up study. <i>Psychiatry Research</i> , 2016, 244, 394-402.	1.7	40
635	A systematic review of the effects of low-frequency repetitive transcranial magnetic stimulation on cognition. <i>Journal of Neural Transmission</i> , 2016, 123, 1479-1490.	1.4	54
636	Implicit motor sequence learning in schizophrenia and in old age: reduced performance only in the third session. <i>Experimental Brain Research</i> , 2016, 234, 3531-3542.	0.7	5
637	Developmental vitamin D deficiency and schizophrenia: the role of animal models. <i>Genes, Brain and Behavior</i> , 2016, 15, 45-61.	1.1	32
638	Using the cognitive assessment interview to screen cognitive impairment in psychosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 629-637.	1.8	13
639	Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding. <i>Psychopharmacology</i> , 2016, 233, 3725-3735.	1.5	26

#	ARTICLE	IF	CITATIONS
640	Validation of the cognitively normal range and below normal range subtypes in chronically hospitalized patients with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2016, 5, 28-34.	0.7	4
641	Neuroplastic Changes Following Social Cognition Training in Schizophrenia: A Systematic Review. <i>Neuropsychology Review</i> , 2016, 26, 310-328.	2.5	34
642	Cognitive remediation for individuals with psychosis: efficacy and mechanisms of treatment effects. <i>Psychological Medicine</i> , 2016, 46, 3275-3289.	2.7	20
643	Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. <i>Journal of Psychopharmacology</i> , 2016, 30, 1141-1144.	2.0	28
644	Longitudinal stability of social cognition in schizophrenia: A 5-year follow-up of social perception and emotion processing. <i>Schizophrenia Research</i> , 2016, 176, 467-472.	1.1	48
645	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. <i>Psychological Medicine</i> , 2016, 46, 2133-2144.	2.7	36
646	Psychotic disorders in DSM-5 and ICD-11. <i>CNS Spectrums</i> , 2016, 21, 349-354.	0.7	54
647	Quality of Life, Cognition, and Social Cognition in Schizophrenia. , 2016, , 25-51.		2
648	N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. <i>BMC Psychiatry</i> , 2016, 16, 320.	1.1	34
649	Combining social cognitive treatment, cognitive remediation, and functional skills training in schizophrenia: a randomized controlled trial. <i>NPJ Schizophrenia</i> , 2016, 2, 16037.	2.0	36
650	Negative symptoms are associated with an increased subjective cost of cognitive effort.. <i>Journal of Abnormal Psychology</i> , 2016, 125, 528-536.	2.0	74
651	Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2016, 43, sbw148.	2.3	21
652	Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis. <i>Psychiatry Research</i> , 2016, 243, 198-206.	1.7	26
653	A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 979-1000.	2.9	59
654	Does cognitive remediation modify the use of psychiatric services and the patterns of care of patients with schizophrenia?. <i>Schizophrenia Research</i> , 2016, 175, 85-89.	1.1	5
655	The underlying neurobiology of key functional domains in young people with mood and anxiety disorders: a systematic review. <i>BMC Psychiatry</i> , 2016, 16, 156.	1.1	31
656	Cognitive impairment in schizophrenia across age groups: a case-control study. <i>BMC Psychiatry</i> , 2016, 16, 37.	1.1	24
658	Intrinsic motivation as a mediator between metacognition deficits and impaired functioning in psychosis. <i>British Journal of Clinical Psychology</i> , 2016, 55, 332-347.	1.7	33

#	ARTICLE	IF	CITATIONS
659	Impulsivity across the psychosis spectrum: Correlates of cortical volume, suicidal history, and social and global function. <i>Schizophrenia Research</i> , 2016, 170, 80-86.	1.1	40
660	The association between cognitive deficits and prefrontal hemodynamic responses during performance of working memory task in patients with schizophrenia. <i>Schizophrenia Research</i> , 2016, 172, 114-122.	1.1	18
661	Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 187-194.	1.1	36
662	Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding. <i>Behavioural Brain Research</i> , 2016, 300, 45-55.	1.2	17
663	The dopamine D ₃ -preferring D ₂ /D ₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. <i>European Neuropsychopharmacology</i> , 2016, 26, 208-224.	0.3	49
664	Cognitive Impairment in Schizophrenia: Interplay of BDNF and Childhood Trauma? A Review of Literature. <i>Psychiatric Quarterly</i> , 2016, 87, 559-569.	1.1	11
665	The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia. <i>Schizophrenia Research</i> , 2016, 170, 330-335.	1.1	19
666	The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 587-595.	1.3	41
667	Postsecondary academic achievement and first-episode psychosis: A mixed-methods study. <i>Canadian Journal of Occupational Therapy</i> , 2016, 83, 42-52.	0.8	11
668	Motivational Interviewing to Increase Cognitive Rehabilitation Adherence in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 327-334.	2.3	86
669	A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective $\alpha 7$ Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2016, 173, 827-835.	4.0	50
670	Does cognitive performance map to categorical diagnoses of schizophrenia, schizoaffective disorder and bipolar disorder? A discriminant functions analysis. <i>Journal of Affective Disorders</i> , 2016, 192, 109-115.	2.0	37
671	Sex/gender differences in the brain and cognition in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 67, 57-78.	2.9	195
672	Sex differences in animal models of schizophrenia shed light on the underlying pathophysiology. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 67, 41-56.	2.9	44
673	Predicting employment status and subjective quality of life in patients with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2016, 3, 20-25.	0.7	24
674	Serotonin (5-HT) _{1A} receptor agonism and 5-HT ₇ receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice. <i>Psychopharmacology</i> , 2016, 233, 649-660.	1.5	24
675	State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects. <i>Neuropharmacology</i> , 2016, 102, 244-253.	2.0	23
676	Electrophysiological Correlates of Aberrant Motivated Attention and Salience Processing in Unaffected Relatives of Schizophrenia Patients. <i>Clinical EEG and Neuroscience</i> , 2016, 47, 11-23.	0.9	10

#	ARTICLE	IF	CITATIONS
677	Evidence for Accelerated Decline of Functional Brain Network Efficiency in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 753-761.	2.3	39
678	Psychosocial functioning in first-episode psychosis and associations with neurocognition, social cognition, psychotic and affective symptoms. <i>Microbial Biotechnology</i> , 2017, 11, 23-36.	0.9	46
679	Driving skills in unmedicated first- and recurrent-episode schizophrenic patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 83-88.	1.8	13
680	Distinct profiles of social skill in adults with autism spectrum disorder and schizophrenia. <i>Autism Research</i> , 2017, 10, 878-887.	2.1	45
681	Action-based cognitive remediation for individuals with serious mental illnesses: Effects of real-world simulations and goal setting on functional and vocational outcomes.. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 53-60.	0.8	63
682	MKT+. , 2017, , .		5
683	Language context processing deficits in schizophrenia: The role of attentional engagement. <i>Neuropsychologia</i> , 2017, 96, 262-273.	0.7	12
684	Predictors of current functioning and functional decline in schizophrenia. <i>Schizophrenia Research</i> , 2017, 188, 158-164.	1.1	37
685	Design and synthesis of a novel series of 4-heteroaryl-amino-1-azaspiro[oxazole-5,3-bicyclo[2.2.2]octanes as $\alpha 7$ nicotinic receptor agonists 2. Development of 4-heteroaryl SAR. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1261-1266.	1.0	8
686	Functioning in patients with schizophrenia: a systematic review of the literature using the International Classification of Functioning, Disability and Health (ICF) as a reference. <i>Quality of Life Research</i> , 2017, 26, 531-543.	1.5	20
687	Association of fronto-temporal function with cognitive ability in schizophrenia. <i>Scientific Reports</i> , 2017, 7, 42858.	1.6	9
688	Does Integrated Neurocognitive Therapy (INT) reduce severe negative symptoms in schizophrenia outpatients?. <i>Schizophrenia Research</i> , 2017, 188, 92-97.	1.1	19
689	BMS-933043, a Selective $\alpha 7$ nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 366-371.	1.3	12
690	Realising stratified psychiatry using multidimensional signatures and trajectories. <i>Journal of Translational Medicine</i> , 2017, 15, 15.	1.8	29
691	Factor analyzing the Norwegian <sc>MATRICS C</sc> consensus Cognitive Battery. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 336-345.	1.0	7
692	Evaluation of a cognitive remediation intervention for college students with psychiatric conditions.. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 103-107.	0.8	8
693	Successful implementation of a cognitive remediation program in everyday clinical practice for individuals living with schizophrenia.. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 87-93.	0.8	9
694	Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia. <i>Neurobiology of Learning and Memory</i> , 2017, 141, 44-52.	1.0	16

#	ARTICLE	IF	CITATIONS
695	Coordinated pluralism as a means to facilitate integrative taxonomies of cognition. <i>Philosophical Explorations</i> , 2017, 20, 129-145.	0.4	34
696	Neurocognitive deficits in schizophrenia. Are we making mountains out of molehills?. <i>Psychological Medicine</i> , 2017, 47, 2602-2612.	2.7	58
697	Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. <i>BMJ Open</i> , 2017, 7, e014938.	0.8	5
698	Effect of childhood trauma on cognitive functions in a sample of Chinese patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2017, 76, 147-152.	1.5	25
699	Prediction of post-stroke functional mobility from the initial assessment of cognitive function. <i>NeuroRehabilitation</i> , 2017, 41, 169-177.	0.5	22
700	Phencyclidine administration during neurodevelopment alters network activity in prefrontal cortex and hippocampus in adult rats. <i>Journal of Neurophysiology</i> , 2017, 118, 1002-1011.	0.9	14
701	Visual perceptual remediation for individuals with schizophrenia: Rationale, method, and three case studies.. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 43-52.	0.8	14
702	EPICOG-SCH: A brief battery to screen cognitive impact of schizophrenia in stable outpatients. <i>Schizophrenia Research: Cognition</i> , 2017, 8, 7-20.	0.7	2
703	Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine. <i>Schizophrenia Bulletin</i> , 2017, 43, 1123-1133.	2.3	26
704	A schizophrenia relevant 5-Choice Serial Reaction Time Task for mice assessing broad monitoring, distractibility and impulsivity. <i>Psychopharmacology</i> , 2017, 234, 2047-2062.	1.5	7
705	The relationship between level of cognitive impairments and functional outcome trajectories in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2017, 190, 144-149.	1.1	43
706	Cognitive remediation and occupational outcome in schizophrenia spectrum disorders: A 2 year follow-up study. <i>Schizophrenia Research</i> , 2017, 185, 122-129.	1.1	23
707	Can repetitive transcranial magnetic stimulation improve neurocognition in schizophrenia when combined with cognitive remediation?. <i>Schizophrenia Research</i> , 2017, 183, 161-162.	1.1	3
708	The association between sleep dysfunction and psychosis-like experiences among college students. <i>Psychiatry Research</i> , 2017, 248, 6-12.	1.7	38
709	Measuring stability of cognitive impairment in inpatients with schizophrenia with alternate forms of the Montreal Cognitive Assessment during acute hospitalization. <i>Psychiatry Research</i> , 2017, 258, 299-304.	1.7	15
710	Intersubjectivity and Psychopathology in the Schizophrenia Spectrum: Complicated We, Compensatory Strategies, and Self-Disorders. <i>Psychopathology</i> , 2017, 50, 321-333.	1.1	22
711	Feasibility and preliminary efficacy of remotely delivering cognitive training to people with schizophrenia using tablets. <i>Schizophrenia Research: Cognition</i> , 2017, 10, 7-14.	0.7	21
712	The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 465-472.	2.2	18

#	ARTICLE	IF	CITATIONS
713	Working memory and prefrontal/temporal hemodynamic responses during post-task period in patients with schizophrenia: A multi-channel near-infrared spectroscopy study. <i>Journal of Psychiatric Research</i> , 2017, 95, 288-298.	1.5	15
714	Canadian Guidelines for the Assessment and Diagnosis of Patients with Schizophrenia Spectrum and Other Psychotic Disorders. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 594-603.	0.9	28
715	Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder. <i>Schizophrenia Research: Cognition</i> , 2017, 9, 1-7.	0.7	20
716	The effect of the muscarinic M 1 receptor antagonist biperiden on cognition in medication free subjects with psychosis. <i>European Neuropsychopharmacology</i> , 2017, 27, 854-864.	0.3	15
717	The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats. <i>Neuroscience Research</i> , 2017, 125, 29-36.	1.0	7
718	Comparison of Neurocognition and Social Cognition between Schizoaffective Disorder, Mood Disorders, and Schizophrenia. <i>Social Work Research</i> , 2017, 41, 169-179.	0.3	2
719	Speed and capacity of working memory and executive function in schizophrenia compared to unipolar depression. <i>Schizophrenia Research: Cognition</i> , 2017, 10, 1-6.	0.7	14
720	Multimodal Neuroimaging in Schizophrenia: Description and Dissemination. <i>Neuroinformatics</i> , 2017, 15, 343-364.	1.5	131
721	Allocating effort and anticipating pleasure in schizophrenia: Relationship with real world functioning. <i>European Psychiatry</i> , 2017, 46, 57-64.	0.1	26
722	Sustaining attention to simple visual tasks: a central deficit in schizophrenia? A systematic review. <i>Annals of the New York Academy of Sciences</i> , 2017, 1408, 32-45.	1.8	21
723	Sustained attention ability in schizophrenia: Investigation of conflict monitoring mechanisms. <i>Clinical Neurophysiology</i> , 2017, 128, 1599-1607.	0.7	10
724	Can cognitive insight predict symptom remission in a first episode psychosis cohort?. <i>BMC Psychiatry</i> , 2017, 17, 54.	1.1	29
725	A review of Indian research on cognitive remediation for schizophrenia. <i>Asian Journal of Psychiatry</i> , 2017, 25, 54-59.	0.9	8
726	Age as a moderator of change following compensatory cognitive training in individuals with severe mental illnesses.. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 70-78.	0.8	20
727	Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. <i>Psychiatry Research</i> , 2017, 247, 84-89.	1.7	18
728	Lifetime psychopathological dimensions, cognitive impairment and functional outcome in psychosis. <i>Schizophrenia Research</i> , 2017, 179, 30-35.	1.1	7
729	The course of cognitive functioning after first-episode of psychosis: A six month follow-up study. <i>Schizophrenia Research</i> , 2017, 182, 31-41.	1.1	4
731	Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 401-408.	1.3	34

#	ARTICLE	IF	CITATIONS
733	Modafinil in schizophrenia: is the risk worth taking?. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219218.	0.2	3
734	Enhancing Neuroplasticity to Augment Cognitive Remediation in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017, 8, 191.	1.3	21
735	Cognitive Training in Schizophrenia. , 2017, , 493-530.		1
736	Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 11, 106.	1.0	37
737	Executive Functioning in Men with Schizophrenia and Substance Use Disorders. Influence of Lifetime Suicide Attempts. <i>PLoS ONE</i> , 2017, 12, e0169943.	1.1	39
738	The Functional Significance of Affect Recognition, Neurocognition, and Clinical Symptoms in Schizophrenia. <i>PLoS ONE</i> , 2017, 12, e0170114.	1.1	7
739	The metabolic basis of cognitive insight in psychosis: A positron emission tomography study. <i>PLoS ONE</i> , 2017, 12, e0175803.	1.1	10
740	Halstead Reitan Battery. , 0, , 702-729.		0
741	Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1. <i>Schizophrenia Bulletin</i> , 2017, 43, 1100-1113.	2.3	2
742	Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis. <i>NeuroImage: Clinical</i> , 2018, 18, 713-719.	1.4	26
743	Estradiol and luteinizing hormone regulate recognition memory following subchronic phencyclidine: Evidence for hippocampal GABA action. <i>Psychoneuroendocrinology</i> , 2018, 91, 86-94.	1.3	16
744	Clinical and cognitive correlates of unsheltered status in homeless persons with psychotic disorders. <i>Schizophrenia Research</i> , 2018, 197, 421-427.	1.1	8
745	What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive <i>v.</i> attitudinal and motivational factors. <i>Psychological Medicine</i> , 2018, 48, 2776-2785.	2.7	51
747	Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. <i>Psychiatry Research</i> , 2018, 263, 1-6.	1.7	55
748	Prefrontal cortical parvalbumin and somatostatin expression and cell density increase during adolescence and are modified by BDNF and sex. <i>Molecular and Cellular Neurosciences</i> , 2018, 88, 177-188.	1.0	41
749	Amendment of traditional assessment measures for the negative symptoms of schizophrenia. <i>European Psychiatry</i> , 2018, 49, 50-55.	0.1	4
750	Neurocognitive and Self-efficacy Benefits of Cognitive Remediation in Schizophrenia: A Randomized Controlled Trial. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 549-562.	1.2	30
751	Disorganization and Insight in Schizophrenia. <i>Activitas Nervosa Superior</i> , 2018, 60, 1-7.	0.4	1

#	ARTICLE	IF	CITATIONS
752	Downregulation of 5-hydroxytryptamine 7 receptor in the medial prefrontal cortex ameliorates impulsive actions in animal models of schizophrenia. <i>Behavioural Brain Research</i> , 2018, 341, 212-223.	1.2	1
753	<scp>TAK</scp> 063, a novel <scp>PDE</scp> 10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 604-614.	1.9	18
754	Physical restraints: An ethical dilemma in mental health services in China. <i>International Journal of Nursing Sciences</i> , 2018, 5, 68-71.	0.5	18
755	The CIRCuiTS study (Implementation of cognitive remediation in early intervention services): protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 183.	0.7	16
756	Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification. <i>Current Topics in Behavioral Neurosciences</i> , 2018, 40, 295-323.	0.8	15
757	Cognition, social cognition and functional disability in early-stage schizophrenia: A study from southern India. <i>Psychiatry Research</i> , 2018, 265, 231-237.	1.7	8
758	Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2018, 199, 395-402.	1.1	74
759	Interleukin-3, symptoms and cognitive deficits in first-episode drug-naïve and chronic medicated schizophrenia. <i>Psychiatry Research</i> , 2018, 263, 147-153.	1.7	11
760	Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2018, 12, 11-19.	0.7	21
761	Clinical symptoms predict concurrent social and global functioning in an early psychosis sample. <i>Microbial Biotechnology</i> , 2018, 12, 177-184.	0.9	14
762	A pilot study of a family cognitive adaptation training guide for individuals with schizophrenia.. <i>Psychiatric Rehabilitation Journal</i> , 2018, 41, 109-117.	0.8	14
763	Electrophysiological correlates of adaptive control and attentional engagement in patients with first episode schizophrenia and healthy young adults. <i>Psychophysiology</i> , 2018, 55, e12820.	1.2	27
764	Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 119-125.	1.1	23
765	Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 219-224.	1.8	21
766	Social Disconnection in Schizophrenia and the General Community. <i>Schizophrenia Bulletin</i> , 2018, 44, 242-249.	2.3	78
767	Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. <i>Neuropharmacology</i> , 2018, 128, 492-502.	2.0	35
768	Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. <i>Psychopharmacology</i> , 2018, 235, 447-458.	1.5	26
769	Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. <i>Schizophrenia Research</i> , 2018, 195, 385-390.	1.1	29

#	ARTICLE	IF	CITATIONS
770	Alive but not well: the limited validity but continued utility of the concept of schizophrenia. <i>Psychological Medicine</i> , 2018, 48, 245-246.	2.7	10
771	Effects of 2-bromoterguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats. <i>Psychopharmacology</i> , 2018, 235, 99-108.	1.5	6
772	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. <i>Psychological Medicine</i> , 2018, 48, 1359-1366.	2.7	37
773	Effectiveness of a treatment guideline for schizophrenia in adolescents: Lessons from a middle-income country. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 192-199.	1.3	2
774	Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. <i>Psychiatry Research</i> , 2018, 262, 542-548.	1.7	29
775	Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 789-802.	1.5	10
776	Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine. <i>Biochemical Pharmacology</i> , 2018, 151, 180-187.	2.0	16
777	Aging of the body and the brain in schizophrenia. <i>Schizophrenia Research</i> , 2018, 196, 1-3.	1.1	11
778	Relationship Between Persistent Negative Symptoms and Findings of Neurocognition and Neuroimaging in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 27-35.	0.9	28
779	Strategy for Semantic Association Memory (SESAME) training: Effects on brain functioning in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2018, 271, 50-58.	0.9	23
780	The effects of adjunctive intranasal oxytocin in patients with schizophrenia. <i>Postgraduate Medicine</i> , 2018, 130, 122-128.	0.9	18
781	From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline. <i>Journal of Psychiatric Research</i> , 2018, 96, 231-238.	1.5	68
782	Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood. <i>Psychopharmacology</i> , 2018, 235, 651-661.	1.5	19
783	Hastening treatment development in bipolar disorder: Evaluation of consensus-based recommendations for cognition trials. <i>Bipolar Disorders</i> , 2018, 20, 70-71.	1.1	3
784	Improving functional outcomes in college and university students with schizophrenia in the Western world. <i>Journal of American College Health</i> , 2018, 66, 61-68.	0.8	2
785	Psychosis as a risk factor for suicidal thoughts and behaviors: a meta-analysis of longitudinal studies. <i>Psychological Medicine</i> , 2018, 48, 765-776.	2.7	42
787	Different levels of facial expression recognition in patients with first-episode schizophrenia: A functional MRI study. <i>Annals of General Psychiatry</i> , 2018, 31, e000014.	1.1	7
788	Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department. <i>Integrated Pharmacy Research & Practice</i> , 2018, Volume 7, 161-171.	0.9	13

#	ARTICLE	IF	CITATIONS
789	Prediction of changes in functional ability of inpatients with schizophrenia using logarithmic and linear regression modelling. <i>Hong Kong Journal of Occupational Therapy</i> , 2018, 31, 76-85.	0.2	0
790	Histaminergic Modulation of Recognition Memory. <i>Handbook of Behavioral Neuroscience</i> , 2018, 27, 415-445.	0.7	0
791	Current Status of Cognitive Remediation for Psychiatric Disorders: A Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 461.	1.3	78
792	A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology. <i>Frontiers in Psychiatry</i> , 2018, 9, 491.	1.3	85
793	Neurocognitive and theory of mind deficits and poor social competence in schizophrenia: The moderating role of social disinterest attitudes. <i>Psychiatry Research</i> , 2018, 270, 459-466.	1.7	15
794	Cognitive Remediation Interventions in Schizoaffective Disorder: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 470.	1.3	3
795	Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. <i>Neuropsychology Review</i> , 2018, 28, 509-533.	2.5	279
796	Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening. <i>Computational Biology and Chemistry</i> , 2018, 77, 52-63.	1.1	6
797	Relationship between social and cognitive functions in people with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2215-2224.	1.0	15
798	Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	24
799	Physical activity pattern and cardiorespiratory fitness in individuals with schizophrenia compared with a population-based sample. <i>Schizophrenia Research</i> , 2018, 201, 98-104.	1.1	25
800	Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. <i>Brain</i> , 2018, 141, 2213-2224.	3.7	32
801	Single transcranial direct current stimulation in schizophrenia: Randomized, cross-over study of neurocognition, social cognition, ERPs, and side effects. <i>PLoS ONE</i> , 2018, 13, e0197023.	1.1	24
802	The impact of intrinsic motivation on session attendance and reliable cognitive improvement in cognitive remediation in schizophrenia. <i>Schizophrenia Research</i> , 2018, 202, 354-360.	1.1	25
803	Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion. <i>Nature Communications</i> , 2018, 9, 3028.	5.8	127
804	Cognitive Remediation in Middle-Aged or Older Inpatients with Chronic Schizophrenia: A Randomized Controlled Trial in Korea. <i>Frontiers in Psychology</i> , 2017, 8, 2364.	1.1	9
805	Early Intervention and a Direction of Novel Therapeutics for the Improvement of Functional Outcomes in Schizophrenia: A Selective Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 39.	1.3	16
806	The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 157.	1.3	103

#	ARTICLE	IF	CITATIONS
807	Stereological Assessments of Neuronal Pathology in Auditory Cortex in Schizophrenia. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 131.	0.9	16
809	Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia?. <i>Journal of Psychiatric Research</i> , 2018, 104, 124-129.	1.5	63
810	Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. <i>Schizophrenia Research</i> , 2018, 202, 106-110.	1.1	12
811	Targeting the dopamine D ₁ receptor or its downstream signalling by inhibiting phosphodiesterase ϵ 1 improves cognitive performance. <i>British Journal of Pharmacology</i> , 2018, 175, 3021-3033.	2.7	24
812	Positive and negative affect in schizophrenia spectrum disorders: A forgotten dimension?. <i>Psychiatry Research</i> , 2018, 267, 148-153.	1.7	9
813	An approach to directly link ICA and seed-based functional connectivity: Application to schizophrenia. <i>NeuroImage</i> , 2018, 179, 448-470.	2.1	41
814	Neuroimaging investigations of dorsal stream processing and effects of stimulus synchrony in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2018, 278, 56-64.	0.9	6
815	Cognitive effects of bilateral high frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pilot study. <i>Brain Imaging and Behavior</i> , 2019, 13, 852-861.	1.1	29
816	Social vs. non-social measures of learning potential for predicting community functioning across phase of illness in schizophrenia. <i>Schizophrenia Research</i> , 2019, 204, 104-110.	1.1	6
817	Psychosis in Emerging Adulthood: Phenomenological, Diagnostic, and Clinical Considerations. <i>Evidence-Based Practice in Child and Adolescent Mental Health</i> , 2019, 4, 141-156.	0.7	10
818	Nicotine effects on cognitive remediation training outcome in people with schizophrenia: A pilot study. <i>Psychiatry Research</i> , 2019, 280, 112498.	1.7	3
819	Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. <i>Advances in Pharmacology</i> , 2019, 86, 153-196.	1.2	12
820	The Hyperfocusing Hypothesis: A New Account of Cognitive Dysfunction in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 991-1000.	2.3	51
821	The Optimal Length of Hospitalization for Functional Recovery of Schizophrenia Patients, a Real-World Study in Chinese People. <i>Psychiatric Quarterly</i> , 2019, 90, 661-670.	1.1	6
822	5-HT ₃ Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. <i>Pharmacological Reviews</i> , 2019, 71, 383-412.	7.1	65
823	Disrupted Habituation in the Early Stage of Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 1004-1012.	1.1	21
824	The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2019, 46, 111-117.	0.9	22
825	Computerized cognitive remediation therapy, REHACOM, in first episode of schizophrenia: A randomized controlled trial. <i>Psychiatry Research</i> , 2019, 281, 112563.	1.7	9

#	ARTICLE	IF	CITATIONS
826	Psychoactive substance use among outpatients with severe mental illness: A comparative study. South African Journal of Psychiatry, 2019, 25, 1111.	0.2	8
827	Raloxifene recovers effects of prenatal immune activation on cognitive task-induced gamma power. Psychoneuroendocrinology, 2019, 110, 104448.	1.3	14
828	Hormonal Contraception and the Brain: Examining Cognition and Psychiatric Disorders. Current Psychiatry Research and Reviews, 2019, 15, 116-131.	0.1	11
829	Discrepancies between Self- and Clinical Staff Members' Perception of Cognitive Functioning among Patients with Schizophrenia Undergoing Long-Term Hospitalization. Occupational Therapy International, 2019, 2019, 1-10.	0.3	2
830	One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. Revista De Psiquiatria Y Salud Mental (English Edition), 2019, 12, 135-140.	0.2	5
831	<p>Associations Of Personality Traits With The Capacity-Performance Discrepancy Of Functional Outcome In Patients With Schizophrenia</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2869-2877.	1.0	5
832	Prospective memory in schizophrenia: A meta-analysis of comparative studies. Schizophrenia Research, 2019, 212, 62-71.	1.1	12
833	Eye movement abnormalities and their association with cognitive impairments in schizophrenia. Schizophrenia Research, 2019, 209, 255-262.	1.1	23
834	Factors Associated With Response and Resistance to Cognitive Remediation in Schizophrenia: A Critical Review. Frontiers in Pharmacology, 2018, 9, 1542.	1.6	19
835	Formative, multimethod case studies of learn to quit, an acceptance and commitment therapy smoking cessation app designed for people with serious mental illness. Translational Behavioral Medicine, 2019, 9, 1076-1086.	1.2	24
836	A comparative study of childhood/adolescent and adult onset schizophrenia: does the neurocognitive and psychosocial outcome differ?. Asian Journal of Psychiatry, 2019, 43, 160-169.	0.9	16
837	Exploring Heterogeneity on the Wisconsin Card Sorting Test in Schizophrenia Spectrum Disorders: A Cluster Analytical Investigation. Journal of the International Neuropsychological Society, 2019, 25, 750-760.	1.2	26
838	Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry, 2019, 18, 146-161.	4.8	348
839	Parallel group ICA+ICA: Joint estimation of linked functional network variability and structural covariation with application to schizophrenia. Human Brain Mapping, 2019, 40, 3795-3809.	1.9	23
840	Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and Therapy, 2019, 8, 215-230.	1.4	16
841	Comparing executive functioning and clinical and sociodemographic characteristics of people with schizophrenia who hold a driver's license to those who do not. Canadian Journal of Occupational Therapy, 2019, 86, 70-80.	0.8	2
842	Impact of social cognitive deficits on community functioning. , 2019, , 89-123.		2
843	Effectiveness of Cognitive Remediation in Early Versus Chronic Schizophrenia: A Preliminary Report. Frontiers in Psychiatry, 2019, 10, 236.	1.3	13

#	ARTICLE	IF	CITATIONS
844	Mental Health and Substance Use Disorders in Patients Diagnosed With Cancer: An Integrative Review of Healthcare Utilization. , 2019, 46, 365-383.		3
845	Three-Year Follow-Up Study Exploring Metacognition and Function in Individuals With First Episode Psychosis. <i>Frontiers in Psychiatry</i> , 2019, 10, 182.	1.3	9
846	Combining CDP-choline and galantamine, an optimized ± 7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia. <i>International Journal of Psychophysiology</i> , 2019, 145, 70-82.	0.5	17
847	The effects of cognitive remediation in patients with affective psychosis: A systematic review. <i>Journal of Affective Disorders</i> , 2019, 255, 188-194.	2.0	3
848	Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 742-759.	1.3	84
849	Social anxiety and negative symptoms as the characteristics of patients with schizophrenia who show competenceâ€“performance discrepancy in social functioning. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 394-399.	1.0	13
850	Disparate effects of first and second generation antipsychotics on cognition in schizophrenia â€“ Findings from the randomized NeSSy trial. <i>European Neuropsychopharmacology</i> , 2019, 29, 720-739.	0.3	29
851	Assessing Outcomes in Schizophrenia in Later Life. , 2019, , 95-111.		0
852	The validation of a new online cognitive assessment tool: The MyCognition Quotient. <i>International Journal of Methods in Psychiatric Research</i> , 2019, 28, e1775.	1.1	24
853	Development and testing of a web-based battery to remotely assess cognitive health in individuals with schizophrenia. <i>Schizophrenia Research</i> , 2019, 208, 250-257.	1.1	15
854	Sensory-targeted cognitive training for schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 211-225.	1.4	9
855	Hypothalamic-pituitary-gonadal axis dysfunction: An innate pathophysiology of schizophrenia?. <i>General and Comparative Endocrinology</i> , 2019, 275, 38-43.	0.8	7
856	Assessment of 3-dimensional wisdom in schizophrenia: Associations with neuropsychological functions and physical and mental health. <i>Schizophrenia Research</i> , 2019, 208, 360-369.	1.1	12
858	WAIS-IV Performance in Patients With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 467-473.	0.5	6
859	Role of Executive Function in Response to a Problem Solving Based Psychoeducational Intervention in Adolescents with Psychosis: The PIENSA Trial Revisited. <i>Journal of Clinical Medicine</i> , 2019, 8, 2108.	1.0	2
860	Daily Functioning in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 615-619.	0.5	4
861	Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research. <i>Frontiers in Psychiatry</i> , 2019, 10, 880.	1.3	28
862	Simulated car driving and its association with cognitive abilities in patients with schizophrenia. <i>Schizophrenia Research</i> , 2019, 204, 171-177.	1.1	15

#	ARTICLE	IF	CITATIONS
863	Neurological soft signs (NSS) and cognitive impairment in chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2019, 16, 17-24.	0.7	22
864	Gender differences in correlates of cognition in first-episode psychosis. <i>Psychiatry Research</i> , 2019, 271, 412-420.	1.7	27
865	The relationship between physical activity, clinical and cognitive characteristics and BDNF mRNA levels in patients with severe mental disorders. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 567-576.	1.3	15
866	Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 606-612.	2.8	47
867	Yoga: Balancing the excitation-inhibition equilibrium in psychiatric disorders. <i>Progress in Brain Research</i> , 2019, 244, 387-413.	0.9	7
868	Decomposing the constituent oscillatory dynamics underlying mismatch negativity generation in schizophrenia: Distinct relationships to clinical and cognitive functioning. <i>International Journal of Psychophysiology</i> , 2019, 145, 23-29.	0.5	12
869	Clinical utility of the dual n-back task in schizophrenia: A functional imaging approach. <i>Psychiatry Research - Neuroimaging</i> , 2019, 284, 37-44.	0.9	16
870	Transcallosal Fiber Disruption and its Relationship with Corresponding Gray Matter Alteration in Patients with Diffuse Axonal Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 1106-1114.	1.7	6
871	Compensatory cognitive training for people with severe mental illnesses in supported employment: A randomized controlled trial. <i>Schizophrenia Research</i> , 2019, 203, 41-48.	1.1	50
872	Translating cognitive behavioral interventions from bench to bedside: The feasibility and acceptability of cognitive remediation in research as compared to clinical settings. <i>Schizophrenia Research</i> , 2019, 203, 49-54.	1.1	19
873	Measuring disorganized speech in schizophrenia: automated analysis explains variance in cognitive deficits beyond clinician-rated scales. <i>Psychological Medicine</i> , 2019, 49, 440-448.	2.7	43
874	Motor skills, cognition, and work performance of people with severe mental illness. <i>Disability and Rehabilitation</i> , 2019, 41, 1396-1402.	0.9	7
875	A meta-analytic review of the relationship between neurocognition, metacognition and functional outcome in schizophrenia. <i>Journal of Mental Health</i> , 2020, 29, 496-505.	1.0	41
876	Cognitive and metacognitive factors predict engagement in employment in individuals with first episode psychosis. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100141.	0.7	7
877	Proxy measures of premortem cognitive aptitude in postmortem subjects with schizophrenia. <i>Psychological Medicine</i> , 2020, 50, 507-514.	2.7	22
878	Cognitive remediation in schizophrenia: the earlier the better?. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e57.	1.8	21
879	Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. <i>Pharmacopsychiatry</i> , 2020, 53, 21-29.	1.7	8
880	Cognitive Remediation to Improve Functional Outcome. , 2020, , 395-418.		2

#	ARTICLE	IF	CITATIONS
881	Community Rehabilitation for Youth with Psychosis Spectrum Disorders. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 225-239.	1.0	2
882	Models of Schizophrenia. A Selective Review of Genetic, Neuropharmacological, Cognitive, and Social Approaches. , 2020, , 37-62.		0
883	A Systematic Review of Studies Reporting Data-Driven Cognitive Subtypes across the Psychosis Spectrum. <i>Neuropsychology Review</i> , 2020, 30, 446-460.	2.5	58
884	Deviation from expected cognitive ability is a core cognitive feature of schizophrenia related to neurophysiologic, clinical and psychosocial functioning. <i>Schizophrenia Research</i> , 2020, 215, 300-307.	1.1	18
885	Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 215, 97-104.	1.1	13
886	Preliminary examination of the validity of the NIH toolbox cognition battery in treatment-resistant psychosis. <i>Clinical Neuropsychologist</i> , 2020, 34, 981-1003.	1.5	2
887	Long-term Changes in Cognitive Functioning in Individuals With Psychotic Disorders. <i>JAMA Psychiatry</i> , 2020, 77, 387.	6.0	102
888	NRG3 contributes to cognitive deficits in chronic patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 215, 134-139.	1.1	26
889	Clinical convergence of autism, schizophrenia, and Alzheimer's disease: The case of social cognition. , 2020, , 21-53.		1
890	Eye movement characteristics in schizophrenia: A recent update with clinical implications. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 2-9.	1.1	57
891	Specificity and Durability of Changes in Auditory Processing Efficiency After Targeted Cognitive Training in Individuals With Recent-Onset Psychosis. <i>Frontiers in Psychiatry</i> , 2020, 11, 857.	1.3	3
892	Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 119, 255-267.	2.9	33
893	The Effects of Combined Social Cognition and Interaction Training and Paliperidone on Early-Onset Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 525492.	1.3	5
894	The French Integrative Psychosocial Rehabilitation Assessment for Complex Situations (FIPRACS): Modelization of an Adapted Assessment Method Toward Long-Term Psychiatric Inpatients With Disabling, Severe and Persistent Mental Illness. <i>Frontiers in Psychiatry</i> , 2020, 11, 540680.	1.3	1
895	Cognitive Rehabilitation and Neuroimaging. , 2020, , .		2
896	Neural anomalies during vigilance in schizophrenia: Diagnostic specificity and genetic associations. <i>NeuroImage: Clinical</i> , 2020, 28, 102414.	1.4	13
897	How Much of an Advance Is the Addition of Samidorphan to Olanzapine?. <i>American Journal of Psychiatry</i> , 2020, 177, 1113-1114.	4.0	8
898	Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms. <i>Psychiatry Research</i> , 2020, 294, 113498.	1.7	3

#	ARTICLE	IF	CITATIONS
899	The role of norepinephrine in the pathophysiology of schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 298-314.	2.9	48
900	Habituation during encoding: A new approach to the evaluation of memory deficits in schizophrenia. <i>Schizophrenia Research</i> , 2020, 223, 179-185.	1.1	6
901	Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1042-1062.	2.5	6
902	Major Neuropsychological Impairments in Schizophrenia Patients: Clinical Implications. <i>Current Psychiatry Reports</i> , 2020, 22, 59.	2.1	6
903	CDP-choline and galantamine, a personalized ± 7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study. <i>Psychopharmacology</i> , 2020, 237, 3665-3687.	1.5	7
904	Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 658-663.	0.7	6
905	Network-level mechanisms underlying effects of transcranial direct current stimulation (tDCS) on visuomotor learning. <i>NeuroImage</i> , 2020, 223, 117311.	2.1	14
906	The Cal-DSH diversion guidelines. <i>CNS Spectrums</i> , 2020, 25, 701-713.	0.7	0
907	A cognitive remediation training for young adults with psychotic disorders to support their participation in education“ study protocol for a pilot randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2020, 6, 54.	0.5	3
908	Comparison of cognitive dysfunction between schizophrenia and bipolar disorder patients: A meta-analysis of comparative studies. <i>Journal of Affective Disorders</i> , 2020, 274, 652-661.	2.0	50
909	Cognitive Heterogeneity across Schizophrenia and Bipolar Disorder: A Cluster Analysis of Intellectual Trajectories. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 860-872.	1.2	31
910	The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders. <i>NeuroImage: Clinical</i> , 2020, 27, 102278.	1.4	7
911	Cognitive strengths-based assessment and intervention in first-episode psychosis: A complementary approach to addressing functional recovery?. <i>Clinical Psychology Review</i> , 2020, 79, 101871.	6.0	26
912	Chronic smoking and cognition in patients with schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2020, 222, 113-121.	1.1	20
913	The effect of the AKT1 gene and cannabis use on cognitive performance in healthy subjects. <i>Journal of Psychopharmacology</i> , 2020, 34, 990-998.	2.0	5
914	Negative symptoms in schizophrenia: Modeling the role of experience factor and expression factor. <i>Asian Journal of Psychiatry</i> , 2020, 53, 102182.	0.9	8
915	Predictors of life skills in people with schizophrenia. <i>Journal of Medical Investigation</i> , 2020, 67, 75-82.	0.2	0
916	Prevalence of possible idiopathic normal pressure hydrocephalus in older inpatients with schizophrenia: a replication study. <i>BMC Psychiatry</i> , 2020, 20, 273.	1.1	2

#	ARTICLE	IF	CITATIONS
917	Polymorphism in the 3' UTR of LIF but Not in the ATF6B Gene Associates with Schizophrenia Susceptibility: a Case-Control Study and In Silico Analyses. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 2093-2101.	1.1	13
918	Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models. <i>Frontiers in Neuroscience</i> , 2020, 14, 542.	1.4	37
919	Levels of Structural Integration Mediate the Impact of Metacognition on Functioning in Non-affective Psychosis: Adding a Psychodynamic Perspective to the Metacognitive Approach. <i>Frontiers in Psychology</i> , 2020, 11, 269.	1.1	5
920	Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task. <i>Psychopharmacology</i> , 2020, 237, 1723-1735.	1.5	24
921	Schizophrenia and "unmet needs": From diagnosis to care in Italy. <i>European Psychiatry</i> , 2020, 63, e26.	0.1	9
922	Associations of psychotic-like experiences, related symptoms, and working memory with functioning. <i>European Psychiatry</i> , 2020, 63, e20.	0.1	6
923	Free Thyroxine Concentrations Moderate the Response to a Cognitive Remediation Therapy in People With Early Psychosis: A Pilot Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 636.	1.3	1
924	Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial. <i>Clinical Drug Investigation</i> , 2020, 40, 377-385.	1.1	14
925	Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. <i>BMC Medicine</i> , 2020, 18, 21.	2.3	132
926	Compensatory Cognitive Training for Latino Youth at Clinical High Risk for Psychosis: Study Protocol for a Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 951.	1.3	1
927	Effects of an extrinsic motivator on the evaluation of cognitive and daily living functions in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 220, 172-178.	1.1	1
928	Association between cognitive phenotype in unaffected siblings and prospective 3- and 6-year clinical outcome in their proband affected by psychosis. <i>Psychological Medicine</i> , 2021, 51, 1916-1926.	2.7	2
929	Feasibility and acceptability of cognitive rehabilitation during the acute phase of schizophrenia. <i>Microbial Biotechnology</i> , 2021, 15, 457-462.	0.9	6
930	An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. <i>Psychopharmacology</i> , 2021, 238, 1279-1289.	1.5	27
931	High-intensity interval training and active video gaming improve neurocognition in schizophrenia: a randomized controlled trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 339-353.	1.8	16
932	Relational Memory in the Early Stage of Psychosis: A 2-Year Follow-up Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 75-86.	2.3	12
933	Evaluation of a computer-assisted cognitive remediation program for young people with psychosis: A pilot study. <i>Schizophrenia Research: Cognition</i> , 2021, 23, 100188.	0.7	5
934	Biotyping in psychosis: using multiple computational approaches with one data set. <i>Neuropsychopharmacology</i> , 2021, 46, 143-155.	2.8	25

#	ARTICLE	IF	CITATIONS
935	Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylozapine on working memory in schizophrenia. <i>Journal of Psychopharmacology</i> , 2021, 35, 31-39.	2.0	5
936	Attracting High-Quality Contestants to Contest in the Context of Crowdsourcing Contest Platform. <i>Production and Operations Management</i> , 2021, 30, 1751-1771.	2.1	13
937	Links Between Human and Animal Models of Trauma and Psychosis: A Narrative Review. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 154-165.	1.1	1
938	Does Self-Efficacy Predict Functioning in Older Adults with Schizophrenia? A Cross-Sectional and Longitudinal Mediation Analysis. <i>Cognitive Therapy and Research</i> , 2021, 45, 136-148.	1.2	1
939	Non-Invasive Brain Stimulation Does Not Improve Working Memory in Schizophrenia: A Meta-Analysis of Randomised Controlled Trials. <i>Neuropsychology Review</i> , 2021, 31, 115-138.	2.5	23
940	THEORY OF MIND - NOT EMOTION RECOGNITION - MEDIATES THE RELATIONSHIP BETWEEN EXECUTIVE FUNCTIONS AND SOCIAL FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA. <i>Psychiatria Danubina</i> , 0, 30, 292-298.	0.2	11
941	Tranquilizer/Anxiolytics: Tandospirone. , 2021, , 1-26.		0
942	Cognition and daily life functioning among persons with serious mental illness: A cluster analytic examination of heterogeneity on the Test of Grocery Shopping Skills.. <i>Neuropsychology</i> , 2021, 35, 57-68.	1.0	4
943	Reducing negative symptoms in schizophrenia: Feasibility and acceptability of a combined cognitive-behavioral social skills training and compensatory cognitive training intervention. <i>Psychiatry Research</i> , 2021, 295, 113620.	1.7	10
944	Much of the Neurocognitive Impairment in Schizophrenia is Due to Factors Other Than Schizophrenia Itself: Implications for Research and Treatment. <i>Schizophrenia Bulletin Open</i> , 2021, 2, .	0.9	17
945	Impact of Negative Symptom Domains and Other Clinical Characteristics on Functional Outcomes in Patients with Schizophrenia. <i>Schizophrenia Research and Treatment</i> , 2021, 2021, 1-8.	0.7	8
946	Jobs for People With Mental Health Conditions: Trends and Prospects. <i>Psychiatric Services</i> , 2021, 72, 143-147.	1.1	0
947	Virtual supermarket shopping task for cognitive rehabilitation and assessment of psychiatric patients: Validation in chronic schizophrenia. <i>Ceskoslovenska Psychologie</i> , 2021, 65, 14-30.	0.1	6
948	Predicting Real-World Functioning in Schizophrenia: The Relative Contributions of Neurocognition, Functional Capacity, and Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 639536.	1.3	13
949	Integrative Analyses Followed by Functional Characterization Reveal TMEM180 as a Schizophrenia Risk Gene. <i>Schizophrenia Bulletin</i> , 2021, 47, 1364-1374.	2.3	7
950	A Meta-analysis of Cognitive Remediation for Schizophrenia: Efficacy and the Role of Participant and Treatment Factors. <i>Schizophrenia Bulletin</i> , 2021, 47, 997-1006.	2.3	71
951	Associations Among Increases in Posttraumatic Stress Symptoms, Neurocognitive Performance, and Long-Term Functional Outcomes in U.S. Iraq War Veterans. <i>Journal of Traumatic Stress</i> , 2021, 34, 628-640.	1.0	4
952	Exploring the Interplay Between Adversity, Neurocognition, Social Cognition, and Functional Outcome in People With Psychosis: A Narrative Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 596949.	1.3	13

#	ARTICLE	IF	CITATIONS
953	Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 631589.	1.3	18
954	Bifactor model of cognition in schizophrenia: Evidence for general and specific abilities. <i>Journal of Psychiatric Research</i> , 2021, 136, 132-139.	1.5	2
956	Not Just a Bystander: The Emerging Role of Astrocytes and Research Tools in Studying Cognitive Dysfunctions in Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5343.	1.8	12
957	Executive Dysfunctions in Schizophrenia: A Critical Review of Traditional, Ecological, and Virtual Reality Assessments. <i>Journal of Clinical Medicine</i> , 2021, 10, 2782.	1.0	9
958	Do cognition and other person-level characteristics determine housing outcomes among homeless-experienced adults with serious mental illness?. <i>Psychiatric Rehabilitation Journal</i> , 2021, 44, 176-185.	0.8	1
959	Metacognitive Rating Scale: A Study Applying a Korean Translation to Individuals with Schizophrenia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6853.	1.2	2
960	Flexible versus Fixed Spatial Self-Ordered Response Sequencing: Effects of Inactivation and Neurochemical Modulation of Ventrolateral Prefrontal Cortex. <i>Journal of Neuroscience</i> , 2021, 41, 7246-7258.	1.7	8
961	Common and Distinct Alterations of Cognitive Function and Brain Structure in Schizophrenia and Major Depressive Disorder: A Pilot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 705998.	1.3	7
962	Money talks: The influence of extrinsic motivators on social cognition in early episode psychosis. <i>Schizophrenia Research</i> , 2021, 233, 52-59.	1.1	2
963	Reduced functional connectivity in brain networks underlying paired associates memory encoding in schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, , .	1.1	1
964	Anxiety and executive functions relationships in schizophrenia: A meta-analysis. <i>Personality and Individual Differences</i> , 2021, 177, 110643.	1.6	1
965	Cognitive Remediation in Virtual Environments for Patients with Schizophrenia and Major Depressive Disorder: A Feasibility Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9081.	1.2	1
966	Oculomotor inhibition and location priming in schizophrenia.. <i>Journal of Abnormal Psychology</i> , 2021, 130, 651-664.	2.0	4
967	Targeting synaptic plasticity in schizophrenia: insights from genomic studies. <i>Trends in Molecular Medicine</i> , 2021, 27, 1022-1032.	3.5	17
968	Predictors of social functioning and quality of life in schizophrenia and autism spectrum disorder. <i>Psychiatry Research</i> , 2021, 303, 114087.	1.7	8
969	High Schizotypy Predicts Emotion Recognition Independently of Negative Affect. <i>Frontiers in Psychiatry</i> , 2021, 12, 738344.	1.3	3
970	A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium. <i>Human Brain Mapping</i> , 2022, 43, 352-372.	1.9	39
971	Fronto-parietal network function during cued visual search in the first-episode schizophrenia spectrum. <i>Journal of Psychiatric Research</i> , 2021, 141, 339-345.	1.5	7

#	ARTICLE	IF	CITATIONS
972	Confirmatory Efficacy of Cognitive Enhancement Therapy for Early Schizophrenia: Results From a Multisite Randomized Trial. <i>Psychiatric Services</i> , 2022, 73, 501-509.	1.1	7
973	Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features. <i>American Journal of Psychiatry</i> , 2021, 178, 952-964.	4.0	15
974	Cognitive function mediates the relationship between visual contrast sensitivity and functional outcome in schizophrenia. <i>Journal of Psychiatric Research</i> , 2021, 144, 138-145.	1.5	2
975	The neurocognitive and functional profile of schizophrenia in a genetically homogenous European sample. <i>Psychiatry Research</i> , 2021, 304, 114140.	1.7	2
976	Social brain network predicts real-world social network in individuals with social anhedonia. <i>Psychiatry Research - Neuroimaging</i> , 2021, 317, 111390.	0.9	6
977	Apocynin-tandospirone derivatives demonstrate antioxidant properties in the animal model of schizophrenia. <i>Advances in Redox Research</i> , 2021, 3, 100013.	0.9	1
978	The relationship between cognition and functioning in schizophrenia: A semi-systematic review. <i>Schizophrenia Research: Cognition</i> , 2022, 27, 100217.	0.7	32
979	Impact of aerobic exercise on cognitive function in patients with schizophrenia during daily nursing. <i>Medicine (United States)</i> , 2021, 100, e23876.	0.4	1
980	Psychosocial Rehabilitation and Psychotherapy Approaches. , 2014, , 275-312.		2
981	Assessment of Risk for Psychosis. , 2019, , 7-40.		3
982	Psychologische Grundlagen. , 2010, , 137-213.		1
983	Klinisch-Neuropsychologische Aspekte der Therapie mit Psychopharmaka. , 2010, , 525-549.		1
984	Muscarinic Receptor Pharmacology and Circuitry for the Modulation of Cognition. <i>Handbook of Experimental Pharmacology</i> , 2012, , 121-166.	0.9	92
985	Neuropsychologische Grundlagen. , 2017, , 353-370.		1
986	Electrophysiological Imaging Evaluation of Schizophrenia and Treatment Response. , 2011, , 135-148.		4
987	PSYCHOSIS AND SCHIZOPHRENIA. , 2009, , 797-815.		1
988	Cognition sociale et handicap psychique. , 2014, , 87-98.		1
989	Evidence for inhibited temperament as a transdiagnostic factor across mood and psychotic disorders. <i>Journal of Affective Disorders</i> , 2020, 274, 995-1003.	2.0	3

#	ARTICLE	IF	CITATIONS
990	Impaired meaning-based cognitive skills are specifically associated with poorer subjective quality of life in schizophrenia. <i>Personalized Medicine in Psychiatry</i> , 2020, 23-24, 100062.	0.1	2
991	Modelo predictivo de la funcionalidad en la esquizofrenia: una aproximación desde el modelado de ecuaciones estructurales. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 232-241.	1.0	8
992	Una década del proyecto de primeros episodios psicóticos (PEPs): avanzando hacia una psiquiatría de precisión. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 135-140.	1.0	35
993	Context, goals, and behavioral regulation in schizophrenia: Psychological and neural mechanisms.. , 2009, , 41-76.		2
994	Altered spatial profile of distraction in people with schizophrenia.. <i>Journal of Abnormal Psychology</i> , 2017, 126, 1077-1086.	2.0	25
995	Failures in top-down control in schizophrenia revealed by patterns of saccadic eye movements.. <i>Journal of Abnormal Psychology</i> , 2019, 128, 415-422.	2.0	10
996	Motivational and cognitive correlates of community integration in homeless veterans entering a permanent supported housing program.. <i>American Journal of Orthopsychiatry</i> , 2020, 90, 181-192.	1.0	9
997	Understanding the lived experience of cognitive remediation in schizophrenia: A qualitative comparison with an active control.. <i>Psychiatric Rehabilitation Journal</i> , 2018, 41, 302-311.	0.8	14
999	The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. <i>Neuropsychopharmacology</i> , 2021, 46, 1194-1206.	2.8	21
1000	Communication in schizophrenia, between pragmatics, cognition, and social cognition. <i>Linguistik Aktuell</i> , 0, , 213-234.	0.5	7
1001	Metacognitive Training in Schizophrenia. , 2013, , 358-383.		15
1006	Strategies for pharmacotherapy of schizophrenia. <i>Drugs of the Future</i> , 2008, 33, 0777.	0.0	17
1007	Mismatch Negativity and Cognitive Performance for the Prediction of Psychosis in Subjects with At-Risk Mental State. <i>PLoS ONE</i> , 2013, 8, e54080.	1.1	89
1008	Assessing Long-Term Test-Retest Reliability of the CPT-IP in Schizophrenia. <i>PLoS ONE</i> , 2014, 9, e84780.	1.1	4
1009	The feasibility of vocational rehabilitation in subjects with severe mental illness. <i>Salud Publica De Mexico</i> , 2008, 50, s260-s272.	0.1	3
1010	Profiles of Relationships Between Subjective and Objective Cognition in Schizophrenia: Associations With Quality of Life, Stigmatization, and Mood Factors. <i>Journal of Cognitive Education and Psychology</i> , 2017, 16, 64-76.	0.2	6
1011	Relationships Between World Health Organization<i>International Classification of Functioning, Disability and Health</i>Constructs and Participation in Adults With Severe Mental Illness. <i>Rehabilitation Research Policy and Education</i> , 2016, 30, 286-304.	0.2	14
1012	Neurocognitive deficits in clinical polymorphism of schizophrenia: typology, expression and syndromal overlaps. <i>Bulletin of Siberian Medicine</i> , 2019, 18, 107-118.	0.1	3

#	ARTICLE	IF	CITATIONS
1013	Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. <i>Journal of Psychiatry and Brain Science</i> , 2019, 4, .	0.3	9
1014	Predictors of social cognition in patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2006, 2, 571-576.	1.0	1
1015	Treating Schizophrenia: Novel Targets for the Cholinergic System. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 241-256.	0.8	23
1016	Neuropeptide Systems and Schizophrenia. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 619-632.	0.8	36
1017	User-Centered Design of Learn to Quit, a Smoking Cessation Smartphone App for People With Serious Mental Illness. <i>JMIR Serious Games</i> , 2018, 6, e2.	1.7	91
1018	Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 9-16.	1.8	62
1019	A history of health-related quality of life outcomes in psychiatry. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 127-135.	1.8	78
1020	Technology to assess and support self-management in serious mental illness. <i>Dialogues in Clinical Neuroscience</i> , 2016, 18, 171-183.	1.8	34
1021	Issues and developments related to assessing function in serious mental illness. <i>Dialogues in Clinical Neuroscience</i> , 2016, 18, 135-144.	1.8	13
1022	Methodological Challenges in Psychiatric Treatment Adherence Research. <i>Clinical Schizophrenia and Related Psychoses</i> , 2010, 4, 74-91.	1.4	29
1023	5. Les relations entre cognition et handicap psychique dans la schizophr�nie. , 2011, , 135-159.		10
1024	D�ficits cognitifs et difficult�s d'insertion professionnelle chez des personnes pr�sentant une schizophr�nie. <i>Revue Francaise Des Affaires Sociales</i> , 2010, , 237-255.	0.0	7
1025	Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, e12.	1.1	461
1026	Continued Cannabis Use and Outcome in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 632-638.	1.1	31
1027	Complementary and Alternative Medicine (CAM). <i>Journal of Clinical Psychiatry</i> , 2009, 70, 4-6.	1.1	102
1028	Resilience Improves Neurocognition and Treatment Outcomes in Schizophrenia: A Hypothesis. <i>Open Journal of Psychiatry</i> , 2016, 06, 173-187.	0.2	5
1029	A Preliminary Validity Study of the Cambridge Neuropsychological Test Automated Battery for the Assessment of Executive Function in Schizophrenia and Bipolar Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 394.	0.7	37
1030	The Korean Version of the Schizophrenia Cognition Rating Scale: Reliability and Validity. <i>Psychiatry Investigation</i> , 2017, 14, 141.	0.7	5

#	ARTICLE	IF	CITATIONS
1031	The enigmatic phenotype: Relevant signs and symptoms in schizophrenia. <i>European Journal of Psychiatry</i> , 2005, 19, .	0.7	1
1032	Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials. <i>European Journal of Psychiatry</i> , 2009, 23, .	0.7	15
1033	Cognitive Profile Difference Between Allen Cognitive Levels 4 and 5 in Schizophrenia. <i>American Journal of Occupational Therapy</i> , 2011, 65, 453-461.	0.1	12
1034	Description of and Preliminary Findings for Occupational Connections, an Intervention for Inpatient Psychiatry Settings. <i>American Journal of Occupational Therapy</i> , 2016, 70, 7006350010p1-7006350010p5.	0.1	6
1035	Emerging behavioral and psychotherapeutic interventions for schizophrenia. <i>Dusunen Adam</i> , 2016, , 189-201.	0.0	1
1036	The Impact of Acute Phase Domain-Specific Cognitive Function on Post-stroke Functional Recovery. <i>Annals of Rehabilitation Medicine</i> , 2016, 40, 214.	0.6	10
1037	How Reversible is Social Dysfunction in Autistic Spectrum Disorders?. <i>North American Journal of Medicine & Science</i> , 2012, 5, 172.	3.8	1
1038	The Korean Version of the University of California San Diego Performance-based Skills Assessment: Reliability and Validity. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 261-268.	0.9	6
1039	The Relational Trip Task, a novel ecological measure of relational memory: data from a schizophrenia sample. <i>Cognitive Neuropsychiatry</i> , 2021, 26, 421-440.	0.7	2
1040	Psychologische Grundlagen psychischer Erkrankungen. , 2008, , 227-263.		0
1041	AvaliaÃ§Ã£o neuropsicolÃ³gica na esquizofrenia: revisÃ£o sistemÃ¡tica. <i>Revista De Psiquiatria Do Rio Grande Do Sul</i> , 2008, 30, .	0.3	0
1042	The Use of Neurocognitive Endophenotypes in Large-Scale Family Genetic Studies of Schizophrenia. , 2009, , 177-193.		0
1043	Schizophrenia as a Cognitive Disorder: Recent Approaches to Identifying its Core Cognitive Components to Aid Treatment Development. , 2010, , 267-282.		0
1044	Neuropsychological markers and social cognition in schizophrenia. <i>Medical Psychiatry</i> , 2009, , 152-163.	0.2	0
1046	Psychologische Grundlagen psychischer Erkrankungen. , 2011, , 293-333.		0
1047	Contexte. , 2012, , 12-90.		0
1051	Disturbi della cognizione sociale e le loro conseguenze psicosociali. , 2013, , 21-36.		0
1054	Cognitive Impairment in Schizophrenia. , 2013, , 1-7.		0

#	ARTICLE	IF	CITATIONS
1055	K-WAIS-â€¦ Profile in Schizophrenia. The Korean Journal of Clinical Psychology, 2014, 33, 719-734.	0.3	2
1056	Analysis on the Effect of the Cognitive therapy on the Recovery of the Affective Disorder. , 0, , .		0
1057	Neuropsychologie. , 2015, , 1-18.		1
1058	â€œTwo Hitâ€™ Neurodevelopmental Mechanisms in Schizophrenia: Focus on Animal Models and the Role of BDNF. , 2015, , 335-351.		1
1059	Fondamenti teorici. , 2015, , 1-18.		0
1061	The Strategy and Utility of the Endophenotype Approach to Neurobehavioral Function. Innovations in Cognitive Neuroscience, 2016, , 81-102.	0.3	0
1062	Ã‰valuation et remÃ©diation cognitive des troubles fonctionnels. , 2016, , 19-49.		1
1064	2. CapacitÃ© fonctionnelle et fonctionnement en situation rÃ©elle. , 2016, , 193-214.		1
1065	Changes in cognitive performance during supplementation with omega-3 polyunsaturated fatty acids in patients with schizophrenia â€” a systematic review. Psychiatria I Psychologia Kliniczna, 2016, 16, 155-159.	0.3	0
1066	Theoretische Annahmen: Kognitive Verzerrungen bei Wahn. , 2017, , 39-54.		0
1067	Comparison of Cognitive Control Deficits in Patients with Schizophrenia and Their Unaffected First-Degree Relatives. Journal of Korean Neuropsychiatric Association, 2017, 56, 61.	0.2	0
1069	GaÃ±a : entraÃ±amiento de la reconnaissance des Ã©motions faciales. , 2018, , 629-643.		0
1070	Exercise-induced time-dependent changes in plasma BDNF levels in people with schizophrenia. Journal of Novel Physiotherapy and Physical Rehabilitation, 2018, 5, 001-006.	0.1	1
1071	Vie quotidienne, capacitÃ©s fonctionnelles et rÃ©tablissement. , 2018, , 33-45.		0
1073	COGNITIVE DETERMINANTS OF REAL WORLD SOCIAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA. Journal of Evidence Based Medicine and Healthcare, 2018, 5, 2752-2759.	0.0	0
1074	ExperiÃªncia laboral e inclusÃ£o social de indivÃ©duos com esquizofrenia. Revista Brasileira De SaÃºde Ocupacional, 0, 44, .	0.2	1
1076	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. Schizophrenia Research: Cognition, 2022, 28, 100222.	0.7	10
1077	Comparison of Cognitive Control Deficits in Patients with Schizophrenia and Bipolar I Disorder. Journal of Korean Neuropsychiatric Association, 2020, 59, 236.	0.2	0

#	ARTICLE	IF	CITATIONS
1078	Positive Psychiatry and successful aging in people with schizophrenia. , 2020, , 149-160.		0
1081	Social motivation and behavior in first-episode psychosis: Unique contributions to social quality of life and social functioning. Journal of Psychiatric Research, 2021, 144, 441-447.	1.5	3
1082	Cognitive markers related to long-term remission status in Schizophrenia Spectrum Disorders. Psychiatry Research, 2020, 289, 113035.	1.7	4
1083	Clinical symptoms and social functioning in schizophrenia. Revista De Psiquiatria Y Salud Mental, 2020, , .	1.0	1
1088	Symptom severity is more closely associated with social functioning status in inpatients with schizophrenia than cognitive deficits. Shanghai Archives of Psychiatry, 2012, 24, 83-90.	0.7	0
1089	The effectiveness of computerized cognitive rehabilitation training program in improving cognitive abilities of schizophrenia clients. Iranian Journal of Psychiatry, 2014, 9, 209-15.	0.4	3
1090	Prospective memory impairments in schizophrenic patients. Iranian Journal of Psychiatry and Behavioral Sciences, 2014, 8, 57-63.	0.1	5
1091	Three-way parallel group independent component analysis: Fusion of spatial and spatiotemporal magnetic resonance imaging data. Human Brain Mapping, 2022, 43, 1280-1294.	1.9	10
1092	Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: A preliminary study. Acta Neurologica Scandinavica, 2022, 145, 348-359.	1.0	5
1093	Chapitre 1. Schizophr�nie(s): cliniques. , 2015, , 5-18.		0
1094	Sheltered employment in schizophrenia is related to disorganization symptoms, processing speed and metaphor comprehension. Psychiatria Polska, 2020, 54, 935-950.	0.2	1
1097	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. Schizophrenia Research, 2022, 240, 193-203.	1.1	4
1098	Outcome and Cognitive Treatments in Schizophrenia-Spectrum Illness, Past and Present: An Overview. , 2022, , 78-100.		0
1101	The neurobiological characterization of distinct cognitive subtypes in early-phase schizophrenia-spectrum disorders. Schizophrenia Research, 2022, 241, 228-237.	1.1	6
1103	Cognitive and Global Functioning in Patients With First-Episode Psychosis Stratified by Level of Negative Symptoms. A 10-Year Follow-Up Study. Frontiers in Psychiatry, 2022, 13, 841057.	1.3	8
1104	Assessment of cognitive impairment in psychosis spectrum disorders through self-reported and interview-based measures. European Archives of Psychiatry and Clinical Neuroscience, 2022, , 1.	1.8	0
1105	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. Brain Sciences, 2021, 11, 1632.	1.1	12
1106	Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review. Frontiers in Psychiatry, 2021, 12, 779607.	1.3	12

#	ARTICLE	IF	CITATIONS
1107	Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 789179.	1.3	35
1108	Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses. <i>Frontiers in Psychiatry</i> , 2021, 12, 791117.	1.3	15
1109	Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia. <i>CNS Drugs</i> , 2022, 36, 1-16.	2.7	8
1110	Dopamine D3 Receptor, Cognition and Cognitive Dysfunctions in Neuropsychiatric Disorders: From the Bench to the Bedside. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , .	0.8	1
1121	Unreasonable minds and imperfect self-defense. <i>International Journal of Law and Psychiatry</i> , 2022, 82, 101794.	0.5	0
1123	Caregivers' perception of patients' cognitive deficit in schizophrenia and its influence on their quality of life. <i>Psicothema</i> , 2016, 28, 150-5.	0.7	3
1124	Hierarchical Symptom Components in Early Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 893-901.	2.3	6
1125	Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective. <i>Frontiers in Psychiatry</i> , 2022, 13, 868751.	1.3	2
1126	Chapitre 5. Psychoses Ã l'adolescence. , 2014, , 143-178.		0
1127	Cognitive gains as a mechanism of functional capacity improvement in schizophrenia: Results from a multi-site randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2022, 151, 554-560.	1.5	2
1128	Functional Outcomes in a Randomized Controlled Trial of Animal-Assisted Therapy on Middle-Aged and Older Adults with Schizophrenia. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6270.	1.2	3
1131	Schizophrenia Spectrum and Other Psychotic Disorders. , 2022, , .		0
1132	Assessment Measures. , 2022, , .		0
1133	Exploring the link between cognitive deficit, self-esteem, alexithymia, and depressive symptom of schizophrenia. <i>Brain and Behavior</i> , 2022, 12, .	1.0	10
1134	Aberrant functional connectivity within the salience network is related to cognitive deficits and disorganization in psychosis. <i>Schizophrenia Research</i> , 2022, 246, 103-111.	1.1	6
1135	Determinants of Clinical Recovery in Schizophrenia. <i>Comprehensive Approach To Psychiatry</i> , 2022, , 23-43.	0.7	1
1136	Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. <i>CNS Drugs</i> , 2022, 36, 819-858.	2.7	10
1137	Load-dependent functional connectivity deficits during visual working memory in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2022, 153, 174-181.	1.5	4

#	ARTICLE	IF	CITATIONS
1138	Dimensionality analysis of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G). <i>Schizophrenia Research: Cognition</i> , 2022, 29, 100259.	0.7	2
1139	Comparison between Screening Cognitive Impairment in Psychiatry (SCIP-S) and Minimal State Examination (MMSE) in Forensic Psychiatry. Pilot study. <i>Spanish Journal of Legal Medicine</i> , 2022, 48, 92-98.	0.4	0
1140	Cognition, Symptomatology, and Community Living Skills in Schizophrenia. <i>Current Psychiatry Research and Reviews</i> , 2022, 18, .	0.1	0
1141	Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2023, 120, 110619.	2.5	3
1142	Aerobic exercise enhances cognitive training effects in first-episode schizophrenia: randomized clinical trial demonstrates cognitive and functional gains. <i>Psychological Medicine</i> , 2023, 53, 4751-4761.	2.7	14
1143	Schizophrenia classification using machine learning on resting state EEG signal. <i>Biomedical Signal Processing and Control</i> , 2023, 79, 104233.	3.5	22
1144	New Strategies to Improve Cognitive Symptom Domain in the Treatment of Schizophrenia. , 2022, , 19-56.		0
1145	European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. <i>European Psychiatry</i> , 2022, 65, .	0.1	19
1146	Cognitive trajectories following onset of psychosis: a meta-analysis. <i>British Journal of Psychiatry</i> , 2022, 221, 714-721.	1.7	12
1147	A Retrospective Study on the Relationship Between Cognitive Function and Social Function in Patients With Schizophrenia. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 348-356.	0.6	0
1148	The effects of Baduanjin exercise vs. brisk walking on physical fitness and cognition in middle-aged patients with schizophrenia: A randomized controlled trial. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1
1149	Abnormalities in visual cognition and associated impaired interactions between visual and attentional networks in schizophrenia and brief psychotic disorder. <i>Psychiatry Research - Neuroimaging</i> , 2022, 327, 111545.	0.9	1
1150	Neurohemodynamic correlates of BDNF gene expression in schizophrenia patients with working memory deficits: A functional MRI study. <i>Asian Journal of Psychiatry</i> , 2022, 77, 103261.	0.9	1
1151	Exploring the association between brain-derived neurotrophic factor levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients. <i>European Psychiatry</i> , 2022, 65, .	0.1	0
1152	Predictors of personal recovery for individuals with schizophrenia spectrum disorders living in the community. <i>Clinical Psychology and Psychotherapy</i> , 0, , .	1.4	2
1153	A Scoping Review of Measures Used in Early Intervention Services for Psychosis. <i>Psychiatric Services</i> , 2023, 74, 523-533.	1.1	7
1154	Tranquilizer/Anxiolytics: Tandospirone. , 2022, , 2125-2150.		0
1155	Opportunities and challenges for the development of M ₁ muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits. <i>British Journal of Pharmacology</i> , 0, , .	2.7	4

#	ARTICLE	IF	CITATIONS
1156	Working memory processing deficit associated with a nonlinear response pattern of the anterior cingulate cortex in first-episode and drug-naïve schizophrenia. <i>Neuropsychopharmacology</i> , 2023, 48, 552-559.	2.8	2
1157	Rethinking Immunity and Cognition in Clinical High Risk for Psychosis. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , .	0.8	0
1158	A combined exercise and cognitive training intervention induces fronto-cingulate cortical plasticity in first-episode psychosis patients. <i>Schizophrenia Research</i> , 2023, 251, 12-21.	1.1	4
1159	Influence of cardiovascular risk factors on the cognitive functions of schizophrenia patients. <i>Vestnik Nevrologii, Psihatrii I Nejrohirurgii</i> , 2022, , 837-844.	0.0	0
1160	Clinical symptoms and social functioning in schizophrenia. <i>Revista De PsihiatrĂa Y Salud Mental (English Edition)</i> , 2022, 15, 251-258.	0.2	0
1161	Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e062570.	0.8	1
1162	Differences in white matter microstructure in first-episode schizophrenia spectrum disorders vs healthy volunteers and their association with cognition. <i>Schizophrenia Research</i> , 2022, 250, 196-202.	1.1	0
1163	Hemispheric lateralization of semantic processing before and after aripiprazole treatment in first-episode psychosis or ultra-high risk state. , 2022, 8, .		2
1164	Study of recovery model implementation in psychiatric hospitals: Clients and multidisciplinary staff perspective. <i>International Journal of Mental Health Nursing</i> , 2023, 32, 603-614.	2.1	1
1165	Developmental trajectories of premorbid functioning predict cognitive remediation treatment response in first-episode schizophrenia. <i>Psychological Medicine</i> , 0, , 1-10.	2.7	0
1166	The Role of Two Factors of Negative Symptoms and Cognition on Social Functioning in Male Patients with Schizophrenia: A Mediator Model. <i>Brain Sciences</i> , 2023, 13, 187.	1.1	0
1167	Evaluating the validity of game-based assessments measuring cognitive function among children and adolescents: A systematic review and meta-analysis. <i>Progress in Brain Research</i> , 2023, , 1-36.	0.9	4
1168	What Drives Animal Fluency Performance in Cantonese-Speaking Chinese Patients with Adult-Onset Psychosis?. <i>Brain Sciences</i> , 2023, 13, 372.	1.1	0
1169	Handling prevents and reverses cognitive deficits induced by sub-chronic phencyclidine in a model for schizophrenia in rats. <i>Physiology and Behavior</i> , 2023, 263, 114117.	1.0	0
1171	Mismatch negativity as an early biomarker of cognitive impairment in schizophrenia. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2023, 59, .	0.4	1
1172	Aberrant hippocampus and amygdala morphology associated with cognitive deficits in schizophrenia. <i>Frontiers in Cellular Neuroscience</i> , 0, 17, .	1.8	1
1173	Aberrant Brain Dynamics in Schizophrenia During Working Memory Task: Evidence From a Replication Functional MRI Study. <i>Schizophrenia Bulletin</i> , 2024, 50, 96-106.	2.3	0
1174	Discrimination in the clinical diagnosis between patients with schizophrenia and healthy controls using eye movement and cognitive functions. <i>Psychiatry and Clinical Neurosciences</i> , 2023, 77, 393-400.	1.0	3

#	ARTICLE	IF	CITATIONS
1175	Mediation Effects of Social Cognition on the Relationship between Neurocognition and Social Functioning in Major Depressive Disorder and Schizophrenia Spectrum Disorders. <i>Journal of Personalized Medicine</i> , 2023, 13, 683.	1.1	1
1180	RemÃ©diation cognitive etÃ©vie quotidienne. , 2023, , 63-82.		0
1181	Facteurs subjectifs etÃ©cognitionÃ©: implications pourÃ©laÃ©remÃ©diation cognitive. , 2023, , 37-61.		0
1195	Schizophrenia or Other Primary Psychotic Disorders. , 2023, , 25-38.		0
1202	The magnitude and variability of neurocognitive performance in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. <i>Translational Psychiatry</i> , 2024, 14, .	2.4	0